

A multimodal neuroimaging and neuropsychological study of visual hallucinations in Alzheimer's disease

Stefania **Pezzoli**, PhD ^{(1), (2)}, Riccardo **Manca**, PhD ⁽³⁾,

Annachiara **Cagnin**, MD ^{(4), (5)}, Annalena **Venneri**, PhD ^{(3), (6)}

for the Alzheimer's Disease Neuroimaging Initiative*

(1) Helen Wills Neuroscience Institute, University of California Berkeley, Berkeley, California, USA

(2) Molecular Biophysics and Integrated Bioimaging, Lawrence Berkeley National Laboratory, Berkeley, California, USA

(3) Department of Life Sciences, Brunel University London, London, UK

(4) Department of Neurosciences, University of Padua, Padua, Italy

(5) Padua Neuroscience Center (PNC), University of Padua, Padua, Italy

(6) Department of Medicine and Surgery, University of Parma, Parma, Italy

Word Count: Abstract 234; manuscript 6518; number of references 58

*Data used in preparation of this article were obtained from the Alzheimer's Disease Neuroimaging Initiative (ADNI) database (adni.loni.usc.edu). As such, the investigators within the ADNI contributed to the design and implementation of ADNI and/or provided data but did not participate in analysis or writing of this report. A complete listing of ADNI investigators can be found at: http://adni.loni.usc.edu/wp-content/uploads/how_to_apply/ADNI_Acknowledgement_List.pdf

Corresponding Author

Annalena Venneri, Brunel University London, Gaskell Building, GASK262, UB8 3PH, UK

E-mail: a.venneri@sheffield.ac.uk

Keywords: visual hallucinations; Alzheimer's disease; MRI; FDG-PET; neuropsychology, visuoconstruction, attention.

ABSTRACT

Background: Hallucinations in Alzheimer's disease (AD) have been linked to more severe cognitive and functional decline. However, research on visual hallucinations (VH), the most common type of hallucinations in AD, is limited. **Objective:** To investigate the cognitive and cerebral macrostructural and metabolic features associated with VH in AD. **Methods:** Twenty-four AD patients with VH, 24 with no VH (NVH), and 24 cognitively normal (CN) matched controls were selected from the Alzheimer's Disease Neuroimaging Initiative (ADNI) database. Differences in regional gray matter (GM) volumes and cognitive performance were investigated with whole brain voxel-based morphometry analyses of MRI structural brain scans, and analyses of neuropsychological tests. Glucose metabolic changes were explored in a subsample of patients who had FDG-PET scans available. **Results:** More severe visuoconstructive and attentional deficits were found in AD VH compared with NVH. GM atrophy and hypometabolism were detected in occipital and temporal areas in VH patients in comparison with CN. On the other hand, NVH patients had atrophy and hypometabolism mainly in temporal areas. No differences in GM volume and glucose metabolism were found in the direct comparison between AD VH and NVH. **Conclusion:** In addition to the pattern of brain abnormalities typical of AD, occipital alterations were observed in patients with VH compared with CN. More severe visuoconstructive and attentional deficits were found in AD VH when directly compared with NVH, and might contribute to the emergence of VH in AD.

INTRODUCTION

Although cognitive impairment represents the core feature of Alzheimer's disease (AD), neuropsychiatric symptoms are also common, affect negatively patients' and caregivers' quality of life, and are associated with early institutionalization [1,2]. Hallucinations are observed in a minority of patients with AD, with a prevalence of 13% on average [3], and they have been related to more severe and rapid cognitive impairment [4]. Visual and auditory hallucinations appear to be the most common forms of hallucination in AD, although they can be found in any sensory modality [3,4]. VH in AD have been associated with older age, impaired visual acuity and more severe dementia [5–7]. VH have been identified as the most specific clinical symptom differentiating dementia with Lewy bodies (DLB) from AD in the early stages, and as the only feature suggesting the presence of Lewy bodies (LBs) in cases with mixed AD/LB pathology [8–10].

Hallucinations and delusions have often been investigated together in AD, given their high comorbidity [11]. Studying psychosis in AD as a unitary phenomenon, however, may introduce interpretative issues on symptom-specific neural and cognitive processes that may vary between different psychotic manifestations. In particular, although some studies suggested that visual hallucination may present often with misidentification delusions [12,13], investigations into the neural alterations that may either underlie both hallucinations and delusions or contribute to them individually are lacking. One study comparing 2 patients with AD and VH and 2 patients with paranoid delusions with 5 patients without psychosis found brain hypometabolism in lateral prefrontal and medio-temporal areas in both patient groups with psychosis, but parietal hypometabolism only in the group with VH [14]. Moreover, the neural correlates of misidentification delusions appear to be still not completely understood, since the few studies available have shown hypometabolism in

orbitofrontal and cingulate regions [15] and greater medial temporal lobe atrophy [16] associated with this symptom.

These few and heterogeneous findings suggest a clear need for studies that include carefully characterized groups of patients with AD presenting with specific psychotic symptoms to investigate hallucinations and delusions separately, but also hallucinations in different sensory modalities. Evidence reporting neuropsychological features associated with hallucinations in AD is very limited, and even less for VH. Most studies did not differentiate between sensory modalities, providing, therefore, only partial knowledge of hallucinatory phenomena in this disease. Indeed, recent revisions of both research [13] and clinical criteria [17] for psychosis in neurocognitive disorders have advocated for the distinction of specific psychotic symptoms (e.g. hallucinations in different sensory modalities) in order to advance the understanding of the possible specific causes and treatments. El Haj et al. [4] proposed that hallucinations in AD are the result of a complex interaction between state markers, such as psychological distress and iatrogenic factors, and trait markers, including neurological, sensory and cognitive deficits. In terms of specific cognitive deficits associated with hallucinations, the authors suggested a prominent role of dysfunctional inhibitory mechanisms of irrelevant memories, memory suppression and response inhibition [4,18,19]. A study focusing specifically on VH in AD reported associations with more severe impairments in executive functioning, verbal, visuospatial and semantic memory, as well as more severe global cognitive impairment [20]. Chiu et al. [6] examined the core features of DLB symptomatology in AD patients with VH, who had higher rates of REM sleep behavior disorder (RBD), cognitive fluctuations, severe neuroleptic sensitivity, and other neuropsychiatric and psychotic symptoms when compared with patients without VH. Hallucinating patients were said to have more severe global cognitive impairment, but the use

of screening tests only limited the investigation of more specific cognitive features [6]. Studies detailing the cognitive profile of AD patients with VH are still lacking, as well as those investigating the neural processes involved, suggesting a need for further research. Only a few studies have explored the structural and functional brain features associated with hallucinations in AD, and even less have focused on the visual modality. Some studies reported evidence of brain alterations in the occipital lobe in patients with VH, including smaller occipital/whole brain ratio [21] and higher occipital periventricular hyperintensities scores [22], while other findings suggest a frontal, parietal, and temporal involvement [14], although sample sizes were rather small. In a longitudinal study, Donovan et al. [23] investigated changes in cortical thickness over time in a cohort of 812 participants, including patients with AD dementia, mild cognitive impairment, and cognitive normal individuals from the Alzheimer's disease Neuroimaging Initiative (ADNI) database. The authors found that lower baseline supramarginal cortical thickness predicted the worsening of hallucinations over time, but not reduced thickness of occipital, frontal and superior parietal cortices [23]. Other studies on hallucinations found frontal and insular hypometabolism and gray matter (GM) loss, and parietal hypoperfusion [24,25].

The present study explored trait-related neurocognitive and brain features associated with VH in AD using neuropsychological testing, voxel-based morphometry (VBM) analyses of structural magnetic resonance imaging (MRI) scans, and ¹⁸F-fluorodeoxyglucose (FDG) positron emission tomography (PET). We hypothesized that VH in AD might be associated with cognitive and neural alterations that could possibly resemble those observed in DLB [8,9,26], and expected an involvement of visual perception and attention deficits, in line with the Perception and Attention Deficit (PAD) model of VH [27], and underlying disrupted neural circuits, as contributing factors to VH in AD. We hypothesized occipital and occipito-

temporal volumetric brain abnormalities in hallucinating patients, underlying visual perception impairments, and frontal/subcortical atrophy, sustaining attention deficits [28]. Finally, we expected occipital hypometabolism [26], in line with the hypothesis suggesting a DLB-like profile in AD with VH.

METHODS AND MATERIALS

Study participants and clinical assessment

Data used for this study were obtained from the ADNI database (adni.loni.usc.edu).¹ ADNI inclusion and exclusion criteria are stated in the procedure manuals and clinical protocols available at <http://adni.loni.usc.edu/methods/documents>. Written informed consent was obtained from all ADNI participants, and study protocols were approved by each participating site's institutional review board. All methods were carried out in accordance with the relevant guidelines and regulations. For research governance and compliance with ethical standards and informed consent please consult the ADNI website at www.adni-info.org and associated material. All data contained in the ADNI database are anonymized and publicly available. Approval for secondary analyses of this dataset was granted by the Research Committee of Brunel University of London (reference number 30422-TISS-Jul/2021- 33453-2).

¹ The ADNI was launched in 2003 as a public-private partnership, led by Principal Investigator Michael W. Weiner, MD. The primary goal of ADNI has been to test whether serial MRI, PET, other biological markers, and clinical and neuropsychological assessment can be combined to measure the progression of mild cognitive impairment (MCI) and early AD. The development and use of optimized methods have the purpose of identifying specific biomarkers of AD progression to improve its diagnosis, and to aid the development of new treatments and the assessment of their efficacy [69]. Further details and up-to-date information are available at www.adni-info.org.

From the ADNI cohort, a systematic search for patients with VH was undertaken and participants for whom the following data were available were screened further: T1-weighted MRI scan, Neuropsychiatric Inventory (NPI), Mini Mental State Examination (MMSE) and a comprehensive neuropsychological assessment. Scores were retrieved for the following tests: Trail Making test (TMT), Logical Memory test, Rey Auditory Verbal Learning test (RAVLT), Category Fluency test, Clock Drawing test (CDT) (drawing and copy), Boston Naming test. A detailed description of the clinical protocol, neuropsychiatric and neuropsychological assessments is available at <http://adni.loni.usc.edu/methods>. Data collected within a 6-month period were retrieved for each participant. For patients with data collected at two different time points, the earliest visit was chosen. Consistent with most studies investigating hallucinations in neurodegeneration, we explored trait-related features associated with VH, and differentiated hallucinating and non-hallucinating patients based on whether VH were among the reported clinical features [29]. The presence of VH was assessed with the NPI subsection for VH, namely by answering the question “Does [P] describe seeing things not seen by others or behave as if he/she is seeing things not seen by others (people, animals, lights, etc.)?” with yes/no. Patients in the NVH group had a “no” answer to this question in all assessments available in the ADNI database. Patients were assigned to the VH group if they had a “yes” answer to the relevant question at least in one of the available assessments, suggesting the presence of this symptom as a trait-related feature characterizing their clinical phenotype. In case of visits at multiple time points, the first assessment when patients had a record of the presence of VH was chosen. Six patients were reported as experiencing VH at 2 (n=3) and 3 (n=3) visits. Eight patients presented a fluctuating VH status, with 1 (n=3), 2 (n=4), or 4 (n=1) follow-up visits without VH, and 11 patients did not have a follow-up assessment after the first visit when VH were recorded. Of the 24 selected patients with VH, 12 also presented hallucinations in other sensory

modalities, namely auditory ($n = 8$), tactile ($n = 3$) hallucinations, and a combination of visual, auditory and tactile hallucinations ($n = 1$). Five patients (2 with VH only, 2 with VH and auditory hallucinations and 1 with VH and tactile hallucinations) were also reported talking with people who were not present. Six participants had mild cognitive impairment (MCI) due to suspected AD (including two who had progressed to dementia one year after the assessment selected for this study), and 18 patients with a diagnosis of AD dementia. Subsequently, a group of 24 AD patients with no hallucinations in any sensory modality was selected to match the VH group for age, gender, years of education, MMSE and NPI total score minus the NPI hallucination sub-score. Six participants had MCI due to suspected AD (one of whom progressed to dementia three years after the assessment selected for this study), and 18 had a diagnosis of dementia due to AD. A group of matched cognitively normal (CN) participants ($n = 24$), with no neuropsychiatric symptoms (NPI total score equal to zero) was also identified. Data for all participants ($n=72$) were part of ADNI 2 ($n=68$) and ADNI 3 ($n=4$).

A second sub-study included a sub-sample of patients with VH with FDG-PET available ($n = 11$). Six out of 11 patients with VH also presented other types of hallucinations, specifically auditory ($n = 4$), and tactile ($n = 2$). Additionally, 3 patients (1 with VH only, 1 with VH and auditory hallucinations and 1 with VH and tactile hallucinations) were reported talking with people who were not present. Three patients had MCI due to suspected AD (of whom two progressed to dementia within a 6 to 12-month period), and 8 were diagnosed with AD dementia. A group of 11 patients with MCI ($n = 2$) and dementia ($n = 9$) due to AD with no hallucinations and a group of 11 CN with FDG-PET available were then selected to match the one with VH. Additionally, in order to explore brain metabolism in the overall group of

AD patients irrespectively of hallucination status ($n = 22$), a group of matched CN participants ($n = 22$) with FDG-PET available was identified.

Statistical analyses

Differences in demographic, clinical and neuropsychological measures between patients' groups were assessed using IBM SPSS Statistics 22. The following tests were used as appropriate: one-way ANOVA and independent sample t-test for numerical normally distributed variables, and Mann-Whitney U and Independent-samples Kruskal-Wallis for non-normally distributed variables. The Fisher's Exact Test was used for categorical variables. Bonferroni correction was used as a statistical method for multiple-comparison correction (statistical significance reached with a p value $< \alpha/n$, where α is equal to the p value for each comparison ($p=0.05$) and n the number of comparisons).

MRI and FDG-PET imaging and analyses

MRI acquisition protocols are available at <http://adni.loni.usc.edu/methods>. VBM pre-processing and statistical analyses were carried out using the Statistical Parametric Mapping (SPM) 12 software (Wellcome Centre for Human Neuroimaging, London, UK), running on MATLAB R2014a, version 8.3 (The MathWorks, Inc, Natick, Massachusetts). Structural MRI data were manually reoriented to the Anterior Commissure-Posterior Commissure line, segmented into GM, white matter (WM) and cerebrospinal fluid (CSF), spatially normalized to the Montreal Neurological Institute (MNI) space, modulated and smoothed using a full width half maximum (FWHM) 8 mm isotropic Gaussian kernel. Total GM, WM, and CSF volumes were determined from each image in native space using the MATLAB 'get_totals' script (http://www0.cs.ucl.ac.uk/staff/g.ridgway/vbm/get_totals.m). Total intracranial volume (TIV) was calculated by summing GM, WM and CSF total volumes for each patient.

A GLM analysis with TIV and age as covariates of no interest was carried out to explore pair-wise between-group differences: VH vs NVH, VH vs CN, NVH vs CN. A confirmatory analysis was carried out selecting only patients with VH but no hallucinations in other sensory modalities ($n = 12$) and matched participants in the NVH and CN groups. Relative threshold masking of 0.2 was applied for GM map analysis. Cluster-forming significance thresholds were $p < 0.05$ FWE-corrected for the full analysis, and $p < 0.0001$ for the VH-only sub-study, and the cluster-level threshold was $p < 0.05$ FWE-corrected for multiple comparisons. MNI coordinates were converted into Talairach coordinates using GingerALE, version 2.3.6 (<http://www.brainmap.org/ale/>), and brain region labels were determined with the Talairach Client, version 2.4.3 (<http://www.talairach.org/client.html>).

All FDG-PET images had been quality controlled by the ADNI PET core team, and pre-processed to harmonize images from different scanners [30]. Details on PET acquisition and pre-processing are described at <http://adni.loni.usc.edu/methods/pet-analysis-method/pet-analysis>. Pre-processed FDG-PET images underwent additional processing steps using SPM12. Firstly, each image was co-registered to the corresponding structural MRI scan and resliced using a trilinear interpolation. The output images were inspected visually to check for the accuracy of this process. Co-registered images were then affine registered into the MNI space using the International Consortium for Brain Mapping (ICBM) standard template available in SPM, with 16 non-linear iterations and non-linear regularization set to 1. Images were resliced by means of a trilinear interpolation and no modulation was applied. Within this step, an FDG-PET template developed for patients with dementia was used, available for download as an extension of SPM at <https://www.fil.ion.ucl.ac.uk/spm/ext> [31]. Images were also intensity normalized to reduce the effect of inter-individual differences in brain metabolism by using the cerebellum as reference region. To do so, an area in the superior

cerebellum, including the vermis, as identified by Rasmussen et al. [32] was used, including the following Automated anatomical labelling (AAL) atlas regions: cerebellum III, IV, V, VI and the whole vermis. Firstly, a mask based on these regions was created with the WFU PickAtlas toolbox, and the signal was extracted for each participant using the MarsBaR (MARSeille Boîte À Région d'Intérêt) toolbox. Then, the entire FDG-PET image for each participant was intensity normalized to the cerebellar region of interest (ROI) mean signal using the SPM12 ImCalc tool. Finally, the images were smoothed using a FWHM 8 mm isotropic Gaussian kernel. All pre-processed images were then used for between-group comparisons of hallucinating and non-hallucinating patients, with TIV and age as covariates of no interest. Similarly, an additional confirmatory sub-group analysis was carried out focusing on patients with hallucinations in the visual modality only ($n = 5$). Cluster-forming significance levels were set at $p < 0.001$ for all analyses (except for the GM map comparisons between AD groups and CN, for which an FWE-corrected cluster-forming threshold $p < 0.05$ was used) and the cluster-level significance threshold was set at $p < 0.05$ FWE-corrected for multiple comparisons. Further analyses were run comparing AD sub-groups and CN participants, reported in supplementary materials. Since hallucinations manifest especially in later disease stages, all voxel-based analyses were replicated by excluding patients with MCI; these analyses are also reported in supplementary materials.

Additionally, we carried out some *post hoc* analyses adopting a region-of-interest (ROI) approach. For these additional analyses, 14 ROIs (7 right-sided and 7 left-sided) in occipito-temporal areas that appeared to be more significantly affected in the AD VH group were selected, namely: the calcarine cortex, the cuneus, the inferior, middle and superior occipital gyri, the fusiform and lingual gyri. Additionally, we also selected 4 control regions more affected by AD pathological changes, i.e. left and right hippocampi and posterior cingulate

cortices. The AAL atlas 2 [33] was used to identify these ROIs and create the binary masks to extract GM volumes and values of FDG-PET signal for all of the participants. ANOVA was used to compare both GM volumes and values of FDG-PET signal across participant groups. Correlations between GM volume and metabolism were also investigated for each ROI in the three separate groups (11 VH, 11 NVH and 11 CN) and in the whole sample of participants with PET images irrespectively of diagnosis ($n = 33$).

Biomarkers

Low levels of CSF β -Amyloid₍₁₋₄₂₎ ($A\beta_{1-42}$) have been associated with cerebral $A\beta$ deposition and represent a valid *in vivo* biomarker of AD pathology [34,35]. Thus, we checked whether CSF $A\beta_{1-42}$ and/or florbetapir (^{18}F -AV45) PET scans were available for all the participants. Methodology has been described in detail elsewhere [10,30,36]. CSF $A\beta_{1-42}$ was considered abnormal at a cut-off of 977 pg/mL or below [37], while florbetapir PET images were considered abnormal with a standardized uptake value ratio (SUVR) above the cut-off of 1.11 [36].

Additionally, we also extracted data on CSF levels of phosphorylated tau (p-tau), a biomarker of fibrillary tau pathology [35]. Values of the p-tau/ $A\beta_{1-42}$ ratio above the cut-off of 0.025 were considered abnormal [37]. Biomarker data closest in time to the date of MRI/FDG-PET assessments were included.

Post hoc neuropathological diagnosis checking

Since VH have been found to be a strong predictor of LB pathology at autopsy, we checked *post hoc* the neuropathological status of AD patients included in the present cohort.

Methodology has been described in detail elsewhere [10].

RESULTS

Demographic, neuropsychiatric and neuropsychological findings

AD patients with and without VH, and CN did not significantly differ in age, gender and years of education. *Post hoc* analyses (Dunn's pairwise test) on the MMSE scores revealed differences between both AD sub-groups and CN ($p < 0.001$), but not between AD VH and NVH ($p = 1.00$). Some patients presented tremor (3 VH and 2 NVH), gait abnormalities (4 VH and 1 NVH), and one patient without VH presented both. Detailed demographic and clinical features are reported in Table 1. Moreover, no significant differences were observed in pharmacological treatments between patient groups (supplementary materials).

-Insert Table 1 about here-

Independent-sample Kruskal-Wallis tests, comparing AD VH, NVH and CN, yielded significant results in all neuropsychological measures ($p \leq 0.001$). *Post hoc* analyses (Bonferroni adjusted p-values from Dunn's pairwise tests) are reported in Table 2. In the direct comparison between AD VH and NVH, significant differences were only detected on the CDT - copy, a measure of visuoconstructive abilities, and on both parts of the TMT, a test of visuo-spatial attention and executive function, but these differences were not statistically significant after applying Bonferroni correction for multiple comparisons across neuropsychological tests (significance threshold at $p < 0.005$). However, when compared

with the CN, only hallucinating patients showed statistically significant deficits in the CDT - copy (Table 2 and Figure 1).

-Insert Table 2 and Figure 1 about here-

Whole brain VBM findings

Whole brain VBM analysis of GM yielded no significant results between AD patients with and without VH. When compared with CN, analysis of both patient sub-groups revealed regions of lower GM volume (Table 3, Table 4 and Figure 2).

-Insert Table 3 and Table 4 and Figure 2 about here-

Overlapping regions of GM loss were located in medial and lateral temporal regions, namely the parahippocampal gyrus and middle temporal gyrus bilaterally, left inferior temporal gyrus, right superior temporal gyrus (Figure 2). Other common areas of reduced GM volume were the following: thalamus and insula bilaterally, and right caudate nucleus, inferior frontal and supramarginal gyri. Additional regions of reduced GM were detected in VH patients in the bilateral middle occipital gyri and in the right anterior cingulate. Decreased volume in temporal regions in patients with no VH extended to the left superior temporal gyrus and uncus. Moreover, they presented GM loss in left parietal regions.

Sub-group analyses restricted to patients with hallucinations in the visual modality only showed similar results. In fact, when compared with CN, the two patient groups presented with divergent patterns of atrophy: mainly in bilateral posterior temporo-occipital and parietal regions for AD VH and in temporal, parietal and frontal areas for the AD NVH (Supplementary materials). Similar results emerged when analyses were restricted only to patients with a diagnosis of dementia excluding those with MCI (Supplementary materials).

PET findings

Demographic, clinical and neuropsychological feature details of this sub-sample of participants, and results of FDG-PET analyses comparing AD patients and CN are reported in supplementary materials. No regional differences in brain metabolism were found between AD VH and AD NVH groups. However, when patient groups were compared with CN, the AD VH sub-group showed hypometabolism in bilateral posterior occipito-temporal cortices, in the posterior cingulate, precuneus and cerebellar areas, while the AD NVH presented with hypometabolism in bilateral inferior and medio-temporal areas only (Table 5 and Figure 3).

-Insert Table 5 and Figure 3 about here-

Confirmatory sub-group analyses of the patients with only VH showed that AD VH had widespread hypometabolism, when compared with CN, in left-lateralized occipito-temporal regions. No differences were found between AD NVH and CN (Supplementary materials). Similar results emerged from the analyses restricted to patients with a diagnosis of dementia only (Supplementary materials).

Post hoc ROI findings

No significant differences in ROI GM volumes were found between patient groups, while the VH group showed more consistent and severe GM volume loss in most occipital areas compared with the CN group (Table S8). Both patient groups showed hippocampal atrophy, while GM reductions in the posterior cingulate cortex were significant only in the NVH vs CN comparison. FDG-PET ROI analyses, instead, showed that the VH group presented with hypometabolism in occipital (bilateral calcarine and cuneus) and occipito-temporal (left lingual gyrus) when compared with the NVH group (Table S8). Hypometabolism was also observed in all the other occipital ROIs in the VH vs CN contrast only. Moreover, although no significant differences were observed between patient groups, the NVH group showed more severe hypometabolism in both hippocampi and the right posterior cingulate when compared with the CN group.

Additionally, a significant association (surviving correction for multiple comparisons) between GM volume and metabolism was found for both hippocampi. These findings were significant when the whole sample was investigated, while they were not replicated in the three separate groups (Table S9).

Biomarkers

In both sub-studies, most patients and CN had biomarkers data available (supplementary materials). In the MRI sub-study, both patient sub-groups had lower CSF A β ₁₋₄₂ and higher p-tau levels, as well as higher florbetapir uptake values than CN. No significant differences

were found between patient sub-groups. The proportion of patients with positive biomarkers for AD pathology (A+T+) was significantly higher than in the CN group, but no significant differences were observed between patients with and without VH.

Similar results emerged from the FDG-PET sub-study: while no differences were found between patient sub-groups, the CN group had higher CSF A β ₁₋₄₂ and lower CSF p-tau levels and florbetapir uptake values than patients with AD and VH. The number of patients with positive biomarkers was also higher than in the CN group, but there were no significant differences between patient sub-groups.

Neuropathological diagnosis

Results of neuropathological examinations were available only for four patients in the MRI sub-study (two with and two without VH), three of whom also had FDG-PET assessment (two with and one without VH). Gross findings included moderate cortical atrophy in the two patients with VH, one of whom also had mild hippocampal atrophy, while the other one had hypopigmentation in both the locus coeruleus and the substantia nigra. No gross findings were reported in the two cases without VH, apart from mild atherosclerosis of the circle of Willis in one case.

Microscopic findings confirmed that all four patients had a primary neuropathological diagnosis of AD, with homogeneous pathology across all cases (Thal phase 4 and Braak stage V). They all presented with frequent cortical neuritic plaques and cerebral amyloid angiopathy was reported to be moderate in one non-hallucinating patient and mild in two patients (one with and one without VH).

All patients had mild arteriolosclerosis mainly as mineralization of blood vessels, observed in both patients without VH and in the patient with VH. The latter also presented with mild acute/subacute microinfarcts and with remote ischemic foci in the hippocampus (CA1 region).

LB pathology was present in the amygdala of one patient without VH, while TDP-43 immunoreactive inclusions were observed in both hallucinating patients in the amygdala and the entorhinal/inferior temporal cortex (both cases), the hippocampus (one case) and the neocortex (one case). Mild neuronal loss in the substantia nigra was also observed in both cases without VH and the patient with VH. Moreover, one of the hallucinating patients had pathological changes in WM. Hippocampal sclerosis and frontotemporal lobar degeneration with tauopathy was not present in any of the 4 patients.

DISCUSSION

The first aim of the present study was to explore the neuropsychological correlates associated with VH in a sample of participants with MCI and dementia due to AD. In the direct comparison between patients with and without VH, the CDT - copy (assessing visuoconstructive abilities) and both parts of the TMT (assessing visuospatial attention and executive functioning) suggested more severe deficits in the AD VH group. Interestingly, non-hallucinating patients performed similarly to CN controls on the CDT - copy, suggesting that a combination of more severe visuoconstructive and visuospatial attention impairments may be associated with the clinical manifestation of VH. Lower scores on the Rey figure copy, assessing visuoconstructive abilities, have been detected previously in association with VH in hallucinating Parkinson's disease (PD) and DLB patients [38–41], and other studies

identified visual perception impairments in patients with VH in PD and DLB [42–44]. Deficits in visual attention in PD and DLB patients with VH have also been reported [28,39,45,46]. These findings, together, are in line with the PAD model that proposes that VH result from the combination of visual perception and attention impairments [27]. In the present study, however, none of the cognitive tests can be considered a pure measure of visuoceptive abilities. In fact, the CDT - copy is a visuoconstructive task that relies on spatial attention, executive functioning, motor planning skills and constructive praxis, in addition to visuoceptive abilities, and this should be considered while interpreting the results of the present study. This limitation is, however, due to the relatively restricted cognitive assessments available within the ADNI database. Therefore, the involvement of other cognitive functions cannot be completely ruled out, including cognitive domains that are not assessed by the neuropsychological battery used in ADNI. Moreover, measures of visual attention (e.g., TMT-A or digit cancellation), and visuoconstruction (e.g., CDT – copy or Rey figure copy) were partially different from previous studies investigating VH in DLB [28,45] and might capture different aspects of analogous cognitive functions. Moreover, VH tend to be less severe and complex in AD compared with DLB. Differential patterns of phenomenological features, as well as different clinical diagnoses, might reflect distinct underlying neurocognitive and biological processes.

As for structural brain alterations, we expected volumetric differences in occipital and occipito-temporal brain regions in AD with VH. No differences were identified in the direct comparison between hallucinating and non-hallucinating patients, probably because the two sub-groups had very similar levels of disease severity, as suggested by the analysis of CSF and PET biomarkers for A β and tau pathology and subtle regional symptom related differences insufficient to survive statistical thresholding. Consistently, our voxel-wise PET

analysis showed no differences in the direct comparison between AD patients with and without VH. *Post hoc* ROI analyses revealed hypometabolism in the occipital lobe in AD patients with VH compared with those without, mainly in primary visual areas and in the cuneus bilaterally. These results, however, did not survive correction for multiple comparisons and thus, they must be interpreted with caution. Indeed, a degree of occipital hypometabolism emerged only when patients with VH were compared with controls, while a similar comparison of patients without hallucinations and controls revealed hypometabolism in bilateral medio-temporal areas. No FDG-PET investigation has previously focused on VH in AD. Other PET and SPECT studies that have explored hallucinations in AD have reported conflicting results, including frontal altered glucose metabolism and reduced parietal blood flow [14,24,25]. Contrasting findings may be due to methodological and clinical differences between studies, including those not distinguishing between hallucinations in different sensory modalities [14,24,25]. Occipital/occipito-temporal atrophy has been related to VH in previous studies of patients with AD and PD, and hypometabolism/hypoperfusion in these regions was found in hallucinating patients with PD and DLB [21,22,29,47,48]. In the present study, although the results of the independent comparisons of both AD sub-groups with CN participants seem to suggest a trend of divergent structural and metabolic alterations in VH and NVH patients (i.e., primarily occipital and temporal in VH and temporal in NVH), we detected no significant differences in the direct comparison between patients with and without VH contrary to our hypothesis. Similar findings emerged also when analyses were restricted only to patients with a diagnosis of dementia. Lack of significant results in the direct patient subgroups comparisons, therefore, suggests either that there are no detectable differences in brain structure and metabolism between AD VH and NVH or that any local symptom related differences might be subtle and insufficient to survive statistical thresholding in small samples. In fact, the small sample size may have affected our findings

due to lack of statistical power, especially when comparing regional glucose metabolism, where the sub-groups were very small (AD VH, n = 11; AD NVH, n = 11). Future studies with increased statistical power may be more informative on whether there are specific differences in GM volume and glucose metabolism between AD VH and NVH, although collection of a bigger sample is complicated by the fact that this symptom is rare in AD. In addition, the chosen imaging modalities might have not been suitable to clarify the mechanisms at the basis of VH in AD. There is evidence that altered functional connectivity, detected using resting-state functional MRI (fMRI), may be related to VH in patients with PD and DLB, especially in the default mode network (DMN) [49–51]. According to Shine et al. [52], VH in PD would be facilitated by the presence of disrupted engagement of attention networks, including overactivity of the DMN. Similar mechanisms may underlie hallucinatory phenomena in AD. Notably, altered DMN connectivity has also been related to delusions in AD [53]. Resting-state fMRI studies may be more clearly informative about the dysfunctional organization of large-scale networks contributing to VH in AD, providing greater mechanistic insight than the sole investigation of structural and metabolic alterations.

The findings of the present study highlight the presence of cognitive changes in AD patients with VH similar to those usually observed in DLB. DLB and PD dementia may be defined as visuo-perceptive, attentional and executive dementias, as opposed to the more severe memory deficits observed in AD [54,55]. In addition, occipital hypometabolism/perfusion is among the supportive biomarkers for the diagnosis of DLB [56]. Thus, the more severe deficits in visuoconstruction (CDT – copy), visuospatial attention (TMT-A) and executive functioning (TMT-B), as well as the more pronounced occipital hypometabolism in patients with AD and VH resemble the alterations usually observed in DLB, irrespectively of the presence of VH. In this study, patients with VH presented a pattern of abnormalities typical of AD, including

temporal atrophy, and parietal and temporal hypometabolism. In addition, all the patients with VH who underwent either CSF or PET assessments, i.e. 22 out of 24 patients, had at least one positive biomarker of AD. Moreover, no differences in posterior cingulate metabolism (i.e. cingulate island sign) were found between patients with and without VH (Supplementary materials). Rates and types of eye diseases (primarily cataracts and decreased eyesight) were also very similar across groups (4 CN, 3 AD NVH and 3 AD VH), thus ruling out a possible role of visual problems as the main cause of VH. Overall, these findings support a diagnosis of AD for the patients with VH included in the present study, who do not appear to be clinically defined DLB cases misdiagnosed as AD, although a possible comorbid synuclein and amyloid neuropathology cannot be ruled out. In a previous study, Chiu et al. [6] demonstrated the presence of DLB core features in AD patients with VH and the authors suggested that among AD patients with VH a high proportion could have LB-associated pathological changes. The present findings, although limited by the lack of neuropathological data, complement those reported by Chiu et al. [6], by showing visuo-perceptive/visuoconstructive deficits in hallucinating AD patients, a pattern of deficits usually distinctive of DLB [56]. A previous study on an ADNI series of 22 autopsies found that all 4 patients with AD and hallucinations had concomitant diffused LB pathology, although the sensory modality of the hallucinatory phenomena was not specified [10]. In our study, none of the hallucinating patients with available neuropathological examination (n=2) had concomitant LB pathology. Instead, TDP-43 proteinopathy was found in the medial temporal lobe of both VH patients, and vascular damage in one case, consistently with a previous study pointing at non-AD pathological changes as risk factors for psychotic symptoms in AD [57]. In the current study, autopsy was available for very few patients, only two with VH, making it difficult to draw any firm conclusions. However, VH have also been reported in pure AD cases. In fact, Thomas et al. [8] found that three out of 19 patients with

autopsy-confirmed pure AD had VH that were, however, less complex than those usually observed in DLB. This finding suggests that the phenomenological features of VH may be very informative in investigating their underlying cognitive and neural mechanisms that may differ in relation to complexity and severity of the symptoms, and might also reflect different patterns of underlying neuropathological features. Given the limited neuropathological data available, it is difficult to draw firm conclusions on the specific neuropathological features related to VH in our sample. Thus, VH in AD may be due to a combination of pathologies, including AD and non-AD neuropathological changes, as well as LB-related pathology, although this hypothesis could not be tested by the present study.

Some limitations need acknowledging. Firstly, the sample size was reasonably small, suggesting a need for additional imaging studies aimed at clarifying the neural substrates of this symptom that is, however, rather rare in AD. Pathological data were available only for four patients, providing limited insight into the underlying neuropathological processes of VH in AD, but still this limited evidence might be useful in future meta-analytical reviews. This paucity of evidence highlights the need for further neuropathological studies that might contribute to clarifying the mechanisms underlying VH in AD, and might test whether VH in this disease are the phenomenological outcome of a combination of pathologies. Moreover, the neuropsychological assessment was limited to tests available in the ADNI cohort. Thus, some cognitive processes previously associated with hallucinations in AD, such as memory suppression, as proposed by El Haj et al. [4], could not be tested. Moreover, since the NPI was used, no information on the phenomenology of VH was included, and this may differ between conditions. Thus, it was not possible to know whether the reported visual hallucinations were complex or simple, and whether the patients also had illusions or other visual misperceptions. In addition, the NPI refers to changes in neuropsychiatric symptoms

over the previous month, and thus the presence of hallucinations outside this time window cannot be completely ruled out. All patients in the NVH group, however, did not present any type of hallucinations in all the available assessments in the ADNI database. The limited time frame of the NPI assessment and the lack of other clinical records has also limited the full application of the revised criteria for diagnosis of psychosis in neurocognitive disorders [13,17]. However, to the best of our knowledge, all patients in the VH group developed this symptom after receiving a diagnosis of neurocognitive disorder and had not been previously affected by psychiatric disorders with psychotic features, ruling out, therefore, potential etiologies for hallucinations alternative to neurodegeneration.

Given the high comorbidity of psychotic symptoms in AD, including hallucinations in different sensory modalities, it is difficult to differentiate completely the brain features underpinning these symptoms taken separately. Previous studies have investigated the brain correlates of hallucinations in AD without specifying the sensory modality [24,25]. Other studies focusing on VH had rather small sample size (considerably smaller than the present study), and no information regarding the presence of hallucinations in other sensory modalities in addition to VH was reported [21,22]. However, it should be noted that, in our sample, of the 24 patients with VH, 12 also presented hallucinations in other sensory modalities. Although half of the patients also presented hallucinations in other sensory modalities, all the individuals in the VH group were characterized by the presence of visual hallucinatory phenomena. In addition, 8 patients presented a fluctuating VH status, and did not present VH in at least one follow-up visit, while it was not possible to verify the presence of VH at follow-up for 11 patients. However, the presence of VH at one of the available assessments suggests that this symptom was part of their clinical phenotype. The lack of data in the ADNI database about disease duration prevented us from fully characterizing our

patient samples also on the basis of this variable. However, disease duration may not be directly associated with severity of either neural damage or symptoms. It has been shown that in autopsy confirmed AD with no concomitant α -synuclein pathology and AD with LBs limited to the amygdala, an earlier VH onset was associated with greater limbic and cortical neurofibrillary tangle (NFT) density [58]. However, the same study reported no differences in Braak NFT stage between patients with and without hallucinations [58]. Although hallucinations are mainly observed in advanced disease stages in patients with AD [59], multiple genetic [60–62], personality [63] and environmental factors [64] may increase the risk of hallucination in some patients independently of disease duration or disease stage, a combination of factors that may also explain the occurrence of VH in some patients with MCI. Another limitation is that FDG-PET was available only for 11 out of the 24 AD patients with hallucination.

To our knowledge, this is the first whole brain VBM and FDG-PET study of VH in AD, a symptom that appears to be rare in AD, considering the limited number of patients experiencing VH within all the ADNI cohorts. In addition to a pattern of disease-specific abnormalities, we found more severe visuoconstructive and attention impairments in association with VH. We did not find, however, significant regional differences in GM volume and glucose metabolism in the direct comparison between patients with and without VH, but only a differential pattern of differences when each group was independently compared with cognitively healthy controls. Future multimodal neuroimaging studies with bigger sample sizes may increase our knowledge on the functional and structural brain differences contributing to the development of this symptom in AD. VH are severe and disabling symptoms, often distressing, that have been associated with increased likelihood of institutionalization and a poor response to treatment [65,66]. Nevertheless, there is currently

no effective targeted treatment, problem that is worsen further by the lack of evidence-based interventions [67,68]. In this context, a wider knowledge of the pathophysiology underlying VH, as well as the detection of disease and symptom-specific biomarkers, might aid current research on the treatment of this symptom, by developing new targets and assessing the efficacy of existing interventions.

AUTHOR CONTRIBUTIONS

S.P. and A.V. conceived and designed the study; S.P. selected the data from ADNI, analyzed the data and drafted the manuscript; R.M. analyzed the data and contributed to writing the manuscript. A.V. and A.C. critically revised, reviewed, and contributed to the writing up of the manuscript. All authors interpreted the data and approved the final version of the manuscript.

DISCLOSURE/CONFLICT OF INTEREST

The authors have no disclosures or conflict of interest.

ACKNOWLEDGEMENTS

Data collection and sharing for this project was funded by the Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health Grant U01 AG024904) and DOD ADNI (Department of Defense award number W81XWH-12-2-0012). ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: AbbVie, Alzheimer's Association; Alzheimer's Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc.; Biogen; Bristol-Myers Squibb Company; CereSpir, Inc.; Cogstate; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; EuroImmun; F. Hoffmann-La

Roche Ltd and its affiliated company Genentech, Inc.; Fujirebio; GE Healthcare; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research & Development, LLC.; Johnson & Johnson Pharmaceutical Research & Development LLC.; Lumosity; Lundbeck; Merck & Co., Inc.; Meso Scale Diagnostics, LLC.; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Takeda Pharmaceutical Company; and Transition Therapeutics. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health (www.fnih.org). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer's Therapeutic Research Institute at the University of Southern California. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of Southern California. A.C. was supported by the "Department of excellence 2018-2022" initiative of the Italian Ministry of education (MIUR) awarded to the Department of Neuroscience - University of Padua.

REFERENCES

- [1] Lane CA, Hardy J, Schott JM (2018) Alzheimer's disease. *Eur J Neurol* **25**, 59–70.
- [2] Zhao QF, Tan L, Wang HF, Jiang T, Tan MS, Xu W, Li JQ, Wang J, Lai TJ, Yu JT (2016) The prevalence of neuropsychiatric symptoms in Alzheimer's disease: Systematic review and meta-analysis. *J Affect Disord* **190**, 264–271.
- [3] Linszen MMJ, Lemstra AW, Dauwan M, Brouwer RM, Scheltens P, Sommer IEC (2018) Understanding hallucinations in probable Alzheimer's disease: Very low prevalence rates in a tertiary memory clinic. *Alzheimers Dement (Amst)* **10**, 358–362.
- [4] El Haj M, Roche J, Jardri R, Kapogiannis D, Gallouj K, Antoine P (2017) Clinical and neurocognitive aspects of hallucinations in Alzheimer's disease. *Neurosci Biobehav Rev*.
- [5] Chapman FM, Dickinson J, McKeith I, Ballard C (1999) Association among visual hallucinations, visual acuity, and specific eye pathologies in Alzheimer's disease: treatment implications. *Am J Psychiatry* **156**, 1983–1985.
- [6] Chiu PY, Hsu MH, Wang CW, Tsai CT, Pai MC (2017) Visual hallucinations in Alzheimer's disease is significantly associated with clinical diagnostic features of dementia with Lewy bodies. *PLoS One* **12**, e0186886.
- [7] Holroyd S, Sheldon-Keller A (1995) A Study of Visual Hallucinations in Alzheimer's Disease. *Am J Geriatr Psychiatry* **3**, 198–205.
- [8] Thomas AJ, Mahin-Babaei F, Saidi M, Lett D, Taylor JP, Walker L, Attems J (2018) Improving the identification of dementia with Lewy bodies in the context of an

- Alzheimer's-type dementia. *Alzheimers Res Ther* **10**, 27.
- [9] Tiraboschi P, Salmon DP, Hansen LA, Hofstetter RC, Thal LJ, Corey-Bloom J (2006) What best differentiates Lewy body from Alzheimer's disease in early-stage dementia? *Brain* **129**, 729–735.
- [10] Toledo JB, Cairns NJ, Da X, Chen K, Carter D, Fleisher A, Householder E, Ayutyanont N, Rontiva A, Bauer RJ, Eisen P, Shaw LM, Davatzikos C, Weiner MW, Reiman EM, Morris JC, Trojanowski JQ (2013) Clinical and multimodal biomarker correlates of ADNI neuropathological findings. *Acta Neuropathol Commun* **1**, 65.
- [11] Murray PS, Kumar S, Demichele-Sweet MA, Sweet RA (2014) Psychosis in Alzheimer's disease. *Biol Psychiatry* **75**, 542–552.
- [12] Cook SE, Miyahara S, Bacanu SA, Perez-Madriñan G, Lopez OL, Kaufer DI, Nimgaonkar VL, Wisniewski SR, DeKosky ST, Sweet RA (2003) Psychotic Symptoms in Alzheimer Disease: Evidence for Subtypes. *Am J Geriatr Psychiatry* **11**, 406–413.
- [13] Fischer CE, Ismail Z, Youakim JM, Creese B, Kumar S, Nuñez N, Ryan Darby R, Di Vita A, D'Antonio F, de Lena C, McGeown WJ, Ramit R, Rasmussen J, Bell J, Wang H, Bruneau MA, Panegyres PK, Lanctôt KL, Agüera-Ortiz L, Lyketsos C, Cummings J, Jeste D V., Sano M, Devanand DP, Sweet RA, Ballard C (2020) Revisiting Criteria for Psychosis in Alzheimer's Disease and Related Dementias: Toward Better Phenotypic Classification and Biomarker Research. *J Alzheimer's Dis* **73**, 1143–1156.
- [14] Lopez OL, Smith G, Becker JT, Meltzer CC, DeKosky ST (2001) The psychotic phenomenon in probable Alzheimer's disease: a positron emission tomography study.

- [15] Mentis MJ, Weinstein EA, Horwitz B, McIntosh AR, Pietrini P, Alexander GE, Furey M, Murphy DGM (1995) Abnormal brain glucose metabolism in the delusional misidentification syndromes: A positron emission tomography study in Alzheimer disease. *Biol Psychiatry* **38**, 443–449.
- [16] McLachlan E, Bousfield J, Howard R, Reeves S (2018) Reduced parahippocampal volume and psychosis symptoms in Alzheimer’s disease. *Int J Geriatr Psychiatry* **33**, 389–395.
- [17] Cummings J, Pinto LC, Cruz M, Fischer CE, Gerritsen DL, Grossberg GT, Hwang TJ, Ismail Z, Jeste D V., Koopmans R, Lanctot KL, Mateos R, Peschin S, Sampaio C, Tsuang D, Wang H, Zhong K, Bain LJ, Sano M (2020) Criteria for Psychosis in Major and Mild Neurocognitive Disorders: International Psychogeriatric Association (IPA) Consensus Clinical and Research Definition. *Am J Geriatr Psychiatry* **28**, 1256–1269.
- [18] El Haj M, Gallouj K, Dehon H, Roche J, Laroï F (2018) Hallucinations in Alzheimer’s disease: failure to suppress irrelevant memories. *Cogn Neuropsychiatry* **23**, 142–153.
- [19] El Haj M, Laroï F, Gely-Nargeot MC, Raffard S (2015) Inhibitory deterioration may contribute to hallucinations in Alzheimer’s disease. *Cogn Neuropsychiatry* **20**, 281–295.
- [20] Quaranta D, Vita MG, Bizzarro A, Masullo C, Piccininni C, Gainotti G, Marra C (2015) Cognitive and behavioral determinants of psychotic symptoms in Alzheimer’s disease. *Dement Geriatr Cogn Disord* **39**, 194–206.
- [21] Holroyd S, Shepherd ML, Downs J. H. 3rd (2000) Occipital atrophy is associated with

- visual hallucinations in Alzheimer's disease. *J Neuropsychiatry Clin Neurosci* **12**, 25–28.
- [22] Lin SH, Yu CY, Pai MC (2006) The occipital white matter lesions in Alzheimer's disease patients with visual hallucinations. *Clin Imaging* **30**, 388–393.
- [23] Donovan NJ, Wadsworth LP, Lorus N, Locascio JJ, Rentz DM, Johnson KA, Sperling RA, Marshall GA (2014) Regional cortical thinning predicts worsening apathy and hallucinations across the Alzheimer disease spectrum. *Am J Geriatr Psychiatry* **22**, 1168–1179.
- [24] Blanc F, Noblet V, Philippi N, Cretin B, Foucher J, Armspach JP, Rousseau F (2014) Right anterior insula: core region of hallucinations in cognitive neurodegenerative diseases. *PLoS One* **9**, e114774.
- [25] Kotrla KJ, Chacko RC, Harper RG, Jhingran S, Doody R (1995) SPECT findings on psychosis in Alzheimer's disease. *Am J Psychiatry* **152**, 1470–1475.
- [26] McKeith IG, Boeve BF, Dickson DW, Halliday G, Taylor JP, Weintraub D, Aarsland D, Galvin J, Attems J, Ballard CG, Bayston A, Beach TG, Blanc F, Bohnen N, Bonanni L, Bras J, Brundin P, Burn D, Chen-Plotkin A, Duda JE, El-Agnaf O, Feldman H, Ferman TJ, Ffytche D, Fujishiro H, Galasko D, Goldman JG, Gomperts SN, Graff-Radford NR, Honig LS, Iranzo A, Kantarci K, Kaufer D, Kukull W, Lee VMY, Leverenz JB, Lewis S, Lippa C, Lunde A, Masellis M, Masliah E, McLean P, Mollenhauer B, Montine TJ, Moreno E, Mori E, Murray M, O'Brien JT, Orimo S, Postuma RB, Ramaswamy S, Ross OA, Salmon DP, Singleton A, Taylor A, Thomas A, Tiraboschi P, Toledo JB, Trojanowski JQ, Tsuang D, Walker Z, Yamada M,

- Kosaka K (2017) Diagnosis and management of dementia with Lewy bodies. *Neurology* **89**, 88–100.
- [27] Collerton D, Perry E, McKeith I (2005) Why people see things that are not there: a novel Perception and Attention Deficit model for recurrent complex visual hallucinations. *Behav Brain Sci* **28**, 737–794.
- [28] Pezzoli S, Cagnin A, Antonini A, Venneri A (2019) Frontal and subcortical contribution to visual hallucinations in dementia with Lewy bodies and Parkinson's disease. *Postgrad Med* **131**, 509–522.
- [29] Pezzoli S, Venneri A (2021) Neuroimaging Findings in Patients with Hallucinations: Evidence from Neurodegenerative and Psychiatric Conditions. In *PET and SPECT in Psychiatry* Springer International Publishing, Cham, pp. 555–587.
- [30] Jagust WJ, Landau SM, Koeppe RA, Reiman EM, Chen K, Mathis CA, Price JC, Foster NL, Wang AY (2015) The Alzheimer's Disease Neuroimaging Initiative 2 PET Core: 2015. *Alzheimers Dement* **11**, 757–771.
- [31] Della Rosa PA, Cerami C, Gallivanone F, Prestia A, Caroli A, Castiglioni I, Gilardi MC, Frisoni G, Friston K, Ashburner J, Perani D (2014) A standardized [18F]-FDG-PET template for spatial normalization in statistical parametric mapping of dementia. *Neuroinformatics* **12**, 575–593.
- [32] Rasmussen JM, Lakatos A, van Erp TG, Kruggel F, Keator DB, Fallon JT, Macciardi F, Potkin SG (2012) Empirical derivation of the reference region for computing diagnostic sensitive (1)(8)fluorodeoxyglucose ratios in Alzheimer's disease based on the ADNI sample. *Biochim Biophys Acta* **1822**, 457–466.

- [33] Rolls ET, Joliot M, Tzourio-Mazoyer N (2015) Implementation of a new parcellation of the orbitofrontal cortex in the automated anatomical labeling atlas. *Neuroimage* **122**, 1–5.
- [34] Dubois B (2018) The Emergence of a New Conceptual Framework for Alzheimer’s Disease. *J Alzheimers Dis* **62**, 1059–1066.
- [35] Jack C. R. J, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, Holtzman DM, Jagust W, Jessen F, Karlawish J, Liu E, Molinuevo JL, Montine T, Phelps C, Rankin KP, Rowe CC, Scheltens P, Siemers E, Snyder HM, Sperling R (2018) NIA-AA Research Framework: Toward a biological definition of Alzheimer’s disease. *Alzheimers Dement* **14**, 535–562.
- [36] Landau SM, Mintun MA, Joshi AD, Koeppe RA, Petersen RC, Aisen PS, Weiner MW, Jagust WJ (2012) Amyloid deposition, hypometabolism, and longitudinal cognitive decline. *Ann Neurol* **72**, 578–586.
- [37] Hansson O, Seibyl J, Stomrud E, Zetterberg H, Trojanowski JQ, Bittner T, Lofke V, Corradini V, Eichenlaub U, Batrla R, Buck K, Zink K, Rabe C, Blennow K, Shaw LM (2018) CSF biomarkers of Alzheimer’s disease concord with amyloid- β PET and predict clinical progression: A study of fully automated immunoassays in BioFINDER and ADNI cohorts. *Alzheimer’s Dement* **14**, 1470–1481.
- [38] Chang YP, Yang YH, Lai CL, Liou LM (2016) Event-Related Potentials in Parkinson’s Disease Patients with Visual Hallucination. *Park Dis* **2016**, 1863508.
- [39] Manganelli F, Vitale C, Santangelo G, Pisciotta C, Iodice R, Cozzolino A, Dubbioso R, Picillo M, Barone P, Santoro L (2009) Functional involvement of central

- cholinergic circuits and visual hallucinations in Parkinson's disease. *Brain* **132**, 2350–2355.
- [40] Shin S, Lee JE, Hong JY, Sunwoo MK, Sohn YH, Lee PH (2012) Neuroanatomical substrates of visual hallucinations in patients with non-demented Parkinson's disease. *J Neurol Neurosurg Psychiatry* **83**, 1155–1161.
- [41] Pezzoli S, Cagnin A, Bussè C, Zorzi G, Fragiaco F, Bandmann O, Venneri A (2021) Cognitive correlates and baseline predictors of future development of visual hallucinations in dementia with Lewy bodies. *Cortex* **142**, 74–83.
- [42] Koerts J, Borg MA, Meppelink AM, Leenders KL, van Beilen M, van Laar T (2010) Attentional and perceptual impairments in Parkinson's disease with visual hallucinations. *Park Relat Disord* **16**, 270–274.
- [43] Mori E, Shimomura T, Fujimori M, Hirono N, Imamura T, Hashimoto M, Tanimukai S, Kazui H, Hanihara T (2000) Visuo-perceptual impairment in dementia with Lewy bodies. *Arch Neurol* **57**, 489–493.
- [44] Ramirez-Ruiz B, Junque C, Marti MJ, Valldeoriola F, Tolosa E (2006) Neuropsychological deficits in Parkinson's disease patients with visual hallucinations. *Mov Disord* **21**, 1483–1487.
- [45] Cagnin A, Gnoato F, Jelcic N, Favaretto S, Zarantonello G, Ermani M, Dam M (2013) Clinical and cognitive correlates of visual hallucinations in dementia with Lewy bodies. *J Neurol Neurosurg Psychiatry* **84**, 505–510.
- [46] Hepp DHH, da Hora CCC, Koene T, Uitdehaag BMM, van den Heuvel OAA, Klein M, van de Berg WDD, Berendse HWW, Foncke EMM (2013) Cognitive correlates of

- visual hallucinations in non-demented Parkinson's disease patients. *Park Relat Disord* **19**, 795–799.
- [47] Pezzoli S, Cagnin A, Bandmann O, Venneri A (2017) Structural and functional neuroimaging of visual hallucinations in lewy body disease: A systematic literature review. *Brain Sci* **7**, 1–32.
- [48] Pezzoli S, Sánchez-Valle R, Solanes A, Kempton MJ, Bandmann O, Shin J IL, Cagnin A, Goldman JG, Merkitich D, Firbank MJ, Taylor J-P, Pagonabarraga J, Kulisevsky J, Blanc F, Verdolini N, Venneri A, Radua J (2021) Neuroanatomical and cognitive correlates of visual hallucinations in Parkinson's disease and dementia with Lewy bodies: Voxel-based morphometry and neuropsychological meta-analysis. *Neurosci Biobehav Rev* **128**,.
- [49] Franciotti R, Delli Pizzi S, Perfetti B, Tartaro A, Bonanni L, Thomas A, Weis L, Biundo R, Antonini A, Onofri M (2015) Default mode network links to visual hallucinations: A comparison between Parkinson's disease and multiple system atrophy. *Mov Disord* **30**, 1237–1247.
- [50] Yao N, Shek-Kwan Chang R, Cheung C, Pang S, Lau KK, Suckling J, Rowe JB, Yu K, Ka-Fung Mak H, Chua SE, Ho SL, McAlonan GM (2014) The default mode network is disrupted in Parkinson's disease with visual hallucinations. *Hum Brain Mapp* **35**, 5658–5666.
- [51] Pezzoli S, De Marco M, Zorzi G, Cagnin A, Venneri A (2021) Functional Brain Connectivity Patterns Associated with Visual Hallucinations in Dementia with Lewy Bodies. *J Alzheimer's Dis Reports* **5**, 311–320.

- [52] Shine JM, Halliday GM, Naismith SL, Lewis SJG (2011) Visual misperceptions and hallucinations in Parkinson's disease: dysfunction of attentional control networks? *Mov Disord* **26**, 2154–2159.
- [53] Qian W, Fischer CE, Churchill NW, Kumar S, Rajji T, Schweizer TA (2019) Delusions in Alzheimer Disease are Associated With Decreased Default Mode Network Functional Connectivity. *Am J Geriatr Psychiatry* **27**, 1060–1068.
- [54] Goldmann Gross R, Siderowf A, Hurtig HI (2008) Cognitive impairment in Parkinson's disease and dementia with lewy bodies: a spectrum of disease. *Neurosignals* **16**, 24–34.
- [55] Collerton D, Burn D, McKeith I, O'Brien J (2003) Systematic review and meta-analysis show that dementia with Lewy bodies is a visual-perceptual and attentional-executive dementia. *Dement Geriatr Cogn Disord* **16**, 229–237.
- [56] McKeith IG, Boeve BF, Dickson DW, Halliday G, Taylor JP, Weintraub D, Aarsland D, Galvin J, Attems J, Ballard CG, Bayston A, Beach TG, Blanc F, Bohnen N, Bonanni L, Bras J, Brundin P, Burn D, Chen-Plotkin A, Duda JE, El-Agnaf O, Feldman H, Ferman TJ, Ffytche D, Fujishiro H, Galasko D, Goldman JG, Gomperts SN, Graff-Radford NR, Honig LS, Iranzo A, Kantarci K, Kaufer D, Kukull W, Lee VMY, Leverenz JB, Lewis S, Lippa C, Lunde A, Masellis M, Masliah E, McLean P, Mollenhauer B, Montine TJ, Moreno E, Mori E, Murray M, O'Brien JT, Orimo S, Postuma RB, Ramaswamy S, Ross OA, Salmon DP, Singleton A, Taylor A, Thomas A, Tiraboschi P, Toledo JB, Trojanowski JQ, Tsuang D, Walker Z, Yamada M, Kosaka K (2017) Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium. *Neurology* **89**, 88–100.

- [57] Fischer CE, Qian W, Schweizer TA, Millikin CP, Ismail Z, Smith EE, Lix LM, Shelton P, Munoz DG (2016) Lewy Bodies, Vascular Risk Factors, and Subcortical Arteriosclerotic Leukoencephalopathy, but not Alzheimer Pathology, are Associated with Development of Psychosis in Alzheimer's Disease. *J Alzheimer's Dis* **50**, 283–295.
- [58] Ferman TJ, Arvanitakis Z, Fujishiro H, Duara R, Parfitt F, Purdy M, Waters C, Barker W, Graff-Radford NR, Dickson DW (2013) Pathology and temporal onset of visual hallucinations, misperceptions and family misidentification distinguishes dementia with Lewy bodies from Alzheimer's disease. *Parkinsonism Relat Disord* **19**, 227–231.
- [59] MC M, JC M, CM R (2015) “Noncognitive” symptoms of early Alzheimer disease: a longitudinal analysis. *Neurology* **84**, 617–622.
- [60] Creese B, Vassos E, Bergh S, Athanasiu L, Johar I, Rongve A, Medbøen IT, Vasconcelos Da Silva M, Aakhus E, Andersen F, Bettella F, Braekhus A, Djurovic S, Paroni G, Proitsi P, Saltvedt I, Seripa D, Stordal E, Fladby T, Aarsland D, Andreassen OA, Ballard C, Selbaek G (2019) Examining the association between genetic liability for schizophrenia and psychotic symptoms in Alzheimer's disease. *Transl Psychiatry* 2019 91 **9**, 1–10.
- [61] DeMichele-Sweet MAA, Weamer EA, Klei L, Vrana DT, Hollingshead DJ, Seltman HJ, Sims R, Foroud T, Hernandez I, Moreno-Grau S, Tárraga L, Boada M, Ruiz A, Williams J, Mayeux R, Lopez OL, Sibille EL, Kamboh MI, Devlin B, Sweet RA (2017) Genetic risk for schizophrenia and psychosis in Alzheimer disease. *Mol Psychiatry* 2018 234 **23**, 963–972.

- [62] Hollingworth P, Sweet R, Sims R, Harold D, Russo G, Abraham R, Stretton A, Jones N, Gerrish A, Chapman J, Ivanov D, Moskvina V, Lovestone S, Priotsi P, Lupton M, Brayne C, Gill M, Lawlor B, Lynch A, Craig D, McGuinness B, Johnston J, Holmes C, Livingston G, Bass NJ, Gurling H, McQuillin A, Holmans P, Jones L, Devlin B, Klei L, Barmada MM, Demirci FY, DeKosky ST, Lopez OL, Passmore P, Owen MJ, O'Donovan MC, Mayeux R, Kamboh MI, Williams J (2011) Genome-wide association study of Alzheimer's disease with psychotic symptoms. *Mol Psychiatry* 2012 1712 **17**, 1316–1327.
- [63] Prior J, Abraham R, Nicholas H, Chan T, Vanvlymen J, Lovestone S, Boothby H (2016) Are premorbid abnormal personality traits associated with behavioural and psychological symptoms in dementia? *Int J Geriatr Psychiatry* **31**, 1050–1055.
- [64] Haj M El, Jardri R, Larøi F, Antoine P (2016) Hallucinations, loneliness, and social isolation in Alzheimer's disease. <http://dx.doi.org/101080/1354680520151121139> **21**, 1–13.
- [65] Waters F, Collerton D, Ffytche DH, Jardri R, Pins D, Dudley R, Blom JD, Mosimann UP, Eperjesi F, Ford S, Laroi F (2014) Visual hallucinations in the psychosis spectrum and comparative information from neurodegenerative disorders and eye disease. *Schizophr Bull* **40 Suppl 4**, S233-45.
- [66] Aynsworth C, Collerton D, Dudley R (2017) Measures of visual hallucinations: Review and recommendations. *Clin Psychol Rev* **57**, 164–182.
- [67] Swann P, O'Brien JT (2018) Management of visual hallucinations in dementia and Parkinson's disease. *Int Psychogeriatr* 1–22.

- [68] Wilson R, Collerton D, Freeston M, Christodoulides T, Dudley R (2016) Is Seeing Believing? The Process of Change During Cognitive-behavioural Therapy for Distressing Visual Hallucinations. *Clin Psychol Psychother* **23**, 285–297.
- [69] Mueller SG, Weiner MW, Thal LJ, Petersen RC, Jack C, Jagust W, Trojanowski JQ, Toga AW, Beckett L (2005) The Alzheimer’s disease neuroimaging initiative. *Neuroimaging Clin N Am* **15**, 869–77, xi–xii.

Figure captions

Figure 1 Differences between AD VH, AD NVH and CN on the Trail Making Test – part A and B and the Clock Drawing test - copy. * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$ (surviving Bonferroni correction).

Figure 2 Regions of reduced GM volume in a) AD VH and b) AD NVH compared with CN (the color bar indicates the z scores with the cluster-level threshold of $p < 0.05$ FWE-corrected for multiple comparisons, with TIV and age as covariates of no interest); and c) regions of overlapping GM loss in VH and NVH patients (yellow), NVH only (red) and VH (green).

Figure 3 Regions of hypometabolism in a) AD VH and b) AD NVH when compared with CN (the color bar indicates the z scores with the cluster-level threshold of $p < 0.05$ FWE-corrected for multiple comparisons, with TIV and age as covariates of no interest); and c) regions of non-overlapping hypometabolism in NVH (red) and VH patients (green).

Table 1 Demographic, clinical and volumetric characteristics of AD patients with and without VH and CN. Mean and SD are reported for each variable unless otherwise specified.

Characteristic	AD VH (n = 24)	AD NVH (n = 24)	CN (n = 24)	p value
<i>Demographics</i>				
Age	75.88 (9.14)	75.75 (8.04)	75.25 (7.93)	0.96 ^a
Gender M:F	9:15	9:15	9:15	-
Years of education	15.79 (2.60)	15.67 (2.67)	16.00 (2.81)	0.75 ^b
<i>Clinical features</i>				
MMSE	22.46 (4.08)	22.88 (2.40)	29.13 (0.99)	<0.001 ^b
NPI total score	17.96 (13.43)	14.04 (13.69)	-	0.14 ^c
NPI tot minus NPI hallucination	15.46 (12.99)	14.04 (13.69)	-	0.44 ^c
Delusions, n (%)	11 (45.8%)	5 (20.8%)	-	0.06 ^d
Hallucinations, n (%)	26 (100.00%)	0 (0.00%)	-	<0.001 ^d
Agitation/aggression, n (%)	9 (37.5%)	7 (29.2%)	-	0.54 ^d
Depression/dysphoria, n (%)	13 (54.2%)	9 (37.5%)	-	0.25 ^d
Anxiety, n (%)	14 (58.3%)	8 (33.3%)	-	0.08 ^d
Elation/euphoria, n (%)	1 (4.2%)	2 (8.3%)	-	.55 ^d
Apathy/indifference, n (%)	10 (41.7%)	13 (54.2%)	-	0.39 ^d
Disinhibition, n (%)	3 (12.5%)	7 (29.2%)	-	0.16 ^d
Irritability/lability, n (%)	12 (50.0%)	5 (20.8%)	-	0.04 ^d
Aberrant motor behavior, n (%)	5 (20.8%)	7 (29.2%)	-	0.51 ^d
Sleep, n (%)	9 (37.5%)	10 (41.7%)	-	.77 ^d
Appetite and eating disorders, n (%)	10 (41.7%)	4 (16.7%)	-	0.57 ^d
<i>Brain volumes (ml)</i>				
Total GM volume	540.21 (63.14)	544.15 (85.88)	594.85 (74.68)	0.02 ^a
Total WM volume	394.00 (47.77)	392.23 (61.47)	390.30 (54.88)	0.97 ^a
Total CSF volume	522.47 (100.75)	531.06 (92.29)	429.42 (96.50)	0.001 ^a
Total intracranial volume	1456.69 (140.70)	1467.44 (146.63)	1414.57 (142.67)	0.41 ^a

AD: Alzheimer's disease; CN: cognitively normal; CSF: cerebrospinal fluid; GM: gray matter; NPI: neuropsychiatric inventory; NVH: no visual hallucinations; VH: visual hallucinations; WM: white matter. ^a One-way ANOVA; ^b Independent-samples Kruskal-Wallis test; ^c Mann-Whitney U test; ^d Fisher's Exact Test.

Table 2 Differences in neuropsychological tests between AD VH, AD NVH and CN (Kruskal-Wallis test). Bonferroni adjusted p-values from Dunn’s pairwise tests (*post hoc* comparisons) are reported.

Test	AD VH		AD NVH		CN		<i>H</i> (p)	<i>Post hoc</i> comparisons (p)		
	<i>n</i>	Mean (SD)	<i>n</i>	Mean (SD)	<i>n</i>	Mean (SD)		VH-NVH	VH-CN	NVH-CN
TMT-A (s)	22	86.6 (49.9)	24	58.2 (28.8)	24	34.1 (11.2)	23.36 (<0.001)	0.02	<0.001	0.04
TMT-B (s)	20	250.1 (83.4)	24	186.4 (93.6)	24	85.3 (40.4)	30.52 (<0.001)	0.02	<0.001	<0.001
Prose M:										
Immediate	23	5.3 (4.3)	23	5.8 (3.7)	24	16.0 (3.0)	41.04 (<0.001)	1.00	<0.001	<0.001
Delayed	23	2.7 (4.6)	23	1.9 (2.3)	24	14.5 (3.6)	44.28 (<0.001)	1.00	<0.001	<0.001
RAVLT:										
Immediate	23	24.0 (11.0)	24	24.5 (6.6)	24	47.4 (11.3)	39.29 (<0.001)	1.00	<0.001	<0.001
Delayed	23	1.0 (3.1)	24	0.4 (0.9)	24	8.2 (4.3)	48.37 (<0.001)	1.00	<0.001	<0.001
CT	23	11.8 (6.0)	24	12.3 (4.8)	24	22.3 (5.7)	35.09 (<0.001)	1.00	<0.001	<0.001
Clock test:										
Drawing	23	2.8 (1.8)	24	3.7 (1.4)	24	4.6 (0.7)	15.41 (<0.001)	0.08	<0.001	0.06
Copying	23	3.8 (1.6)	24	4.7 (0.8)	24	4.9 (0.3)	15.72 (<0.001)	0.01	<0.001	1.00
BNT	20	22.7 (6.4)	24	24.4 (5.4)	23	28.4 (1.9)	15.10 (<0.001)	0.75	0.001	0.02

AD: Alzheimer’s disease; BNT: Boston naming test; CN: cognitively normal; CT: category fluency; HC: healthy controls; M: memory; NVH: no VH; s: seconds; RAVLT: Rey Auditory Verbal Learning Test; SD: standard deviation; TMT: Trail Making Test; VH: visual hallucinations.

Table 3 Regions of lower gray matter volume in AD VH patients compared with CN (FWE-corrected cluster-level threshold of $p < 0.05$ with TIV and age as covariates of no interest, $k > 20$).

Structure		Cluster size	MNI coordinates			T score	Z score	p value
Parahippocampal gyrus	L	2698	-26	-10	-15	9.11	6.79	<0.001
<i>Parahippocampal gyrus (BA 34)</i>	L		-30	4	-22	8.15	6.33	
<i>Parahippocampal gyrus</i>	L		-32	-38	-6	7.68	6.08	
Parahippocampal gyrus	R	2255	27	-8	-16	8.82	6.66	<0.001
<i>Inferior Frontal gyrus (BA 47)</i>	R		34	9	-21	8.39	6.45	
<i>Insula (BA 13)</i>	R		44	10	-15	7.22	5.83	
Inferior Temporal gyrus (BA 20)	L	447	-60	-50	-12	7.36	5.91	<0.001
<i>Middle Temporal gyrus (BA 21)</i>	L		-64	-42	-8	6.95	5.68	
<i>Middle Temporal gyrus (BA 21)</i>	L		-57	-58	0	6.25	5.26	
Thalamus	L	344	-3	-2	3	7.60	6.04	<0.001
Insula (BA 13)	R	38	40	20	0	6.13	5.18	0.004
Anterior cingulate (BA 32)	R	57	3	44	16	6.39	5.34	0.002
Superior temporal gyrus (BA 21)	R	77	52	-24	-2	6.10	5.16	<0.001
Supramarginal gyrus (BA 40)	R	43	58	-48	38	6.00	5.10	0.004
Insula (BA 13)	R	102	45	-4	-2	5.96	5.08	<0.001
<i>Insula (BA 13)</i>	R		40	-8	9	5.62	4.86	
Middle occipital gyrus (BA 19)	L	131	-40	-84	16	6.37	5.34	<0.001
Middle temporal gyrus (BA 21)	R	44	39	-4	-40	6.11	5.17	0.003
Middle temporal gyrus (BA 21)	R	29	60	-18	-21	5.84	5.00	0.006
Middle occipital gyrus (BA 18)	R	23	26	-88	12	6.19	5.22	0.009
Middle occipital gyrus (BA 18)	L	32	-39	-90	-3	5.68	4.89	0.006
Middle temporal gyrus (BA 21)	R	23	63	-27	-8	5.67	4.88	0.009
Fusiform gyrus (BA 19)	L	21	-28	-76	-16	5.62	4.85	0.010
<i>Fusiform gyrus (BA 19)</i>	L		-38	-74	-15	5.60	4.84	

AD: Alzheimer's disease; CN: cognitively normal; BA: Brodmann area; L: left; R: right; VH: visual hallucinations; TIV: total intracranial volume; k: cluster-extent based threshold.

Table 4 Regions of reduced gray matter volume in AD NVH patients compared with CN (FWE-corrected cluster-level threshold of $p < 0.05$ with TIV and age as covariates of no interest, $k > 20$).

Structure		Cluster size	MNI coordinates			T score	Z score	p value ^a
Parahippocampal gyrus	L	3405	-22	-9	-18	9.08	6.78	<0.001
<i>Parahippocampal gyrus (BA 34)</i>	L		-16	-8	-26	8.13	6.32	
<i>Uncus (BA 28)</i>	L		-28	3	-24	7.98	6.24	
Parahippocampal gyrus	R	2653	28	-4	-22	9.26	9.26	<0.001
<i>Thalamus</i>	R		24	-32	-4	6.77	6.77	
<i>Superior temporal gyrus (BA 38)</i>	R		44	9	-15	6.69	5.53	
Caudate head	R	200	2	4	-3	6.85	5.62	<0.001
Inferior temporal gyrus (BA 37)	L	106	-56	-58	-6	6.19	5.22	<0.001
Insula (BA 13)	R	226	44	-4	-2	6.57	5.45	<0.001
Middle temporal gyrus (BA 21)	R	47	57	-20	-24	5.84	5.00	0.003
Posterior cingulate (BA 31)	L	203	-6	-56	26	6.18	5.22	<0.001
<i>Precuneus (BA 31)</i>	L		-9	-46	32	5.99	5.10	
Superior temporal gyrus (BA 38)	R	28	24	18	-36	5.79	5.01	0.007
Insula (BA 13)	L	63	-42	0	-12	5.87	5.02	0.002
<i>Insula (BA 13)</i>	L		-44	-8	-6	5.66	4.88	
Superior temporal gyrus (BA 21)	R	63	54	-24	-3	5.63	4.86	0.002
Parahippocampal gyrus (BA 36)	L	215	-34	-27	-27	6.56	5.45	<0.001
<i>Fusiform gyrus (BA 20)</i>	L		-44	-36	-24	5.85	5.00	
Uncus (BA 28)	R	126	26	-12	-36	6.19	5.22	<0.001
Inferior parietal lobule (BA 40)	L	26	-45	-52	27	6.12	5.18	0.007
Middle temporal gyrus (BA 21)	L	22	-64	-39	-6	5.79	4.96	0.009
Uncus (BA 38)	L	28	-26	4	-45	5.66	4.88	0.007

AD: Alzheimer's disease; CN: cognitively normal; BA: Brodmann area; L: left; R: right; NVH: no visual hallucinations; TIV: total intracranial volume; k: cluster-extent based threshold. ^a cluster-level FWE corrected p value.

Table 5 Regions of hypometabolism in AD patients with and without VH independently compared with CN (FWE-corrected cluster-level threshold of $p < 0.05$ with TIV and age as covariates of no interest).

Structure	Side	Cluster size	MNI coordinates			T score	Z score	p value ^a
AD VH < CN								
Inferior temporal gyrus (BA 20)	R	33798	64	-24	-22	7.90	5.13	<0.001
<i>Inferior occipital gyrus (BA 18)</i>	L		-34	-100	-8	7.17	4.87	
<i>Middle temporal gyrus (BA 19)</i>	R		58	-68	14	6.97	4.79	
<i>Inferior temporal gyrus (BA 20)</i>	R		66	-34	-24	6.97	4.79	
<i>Superior occipital gyrus (BA 19)</i>	L		-32	-86	26	6.88	4.76	
<i>Inferior parietal lobule (BA 39)</i>	R		50	-64	40	6.72	4.7-	
<i>Posterior cingulate (BA 30)</i>	L		-4	-64	8	6.59	4.64	
<i>Middle temporal gyrus (BA 39)</i>	R		54	-68	22	6.50	4.61	
<i>Cerebellum – tuber</i>	R		26	-88	-38	6.45	4.59	
<i>Cerebellum – tuber</i>	R		50	-74	-38	6.43	4.58	
<i>Inferior temporal gyrus (BA 20)</i>	L		-60	-24	-24	6.41	4.57	
<i>Precuneus (BA 19)</i>	L		-30	-80	42	6.28	4.51	
<i>Cerebellum – uvula</i>	L		-14	-88	-32	6.27	4.51	
<i>Middle temporal gyrus (BA 39)</i>	L		-34	-72	28	6.23	4.49	
<i>Precuneus (BA 31)</i>	R		12	-62	20	6.19	4.47	
<i>Cerebellum - tonsil</i>	R		48	-48	-48	6.16	4.46	
Precentral gyrus (BA 9)	L	694	-40	6	34	5.18	4.00	0.049
<i>Middle frontal gyrus (BA 9)</i>	L		-48	18	34	4.37	3.56	
<i>Middle frontal gyrus (BA 9)</i>	L		-22	34	38	4.35	3.55	
-Middle frontal gyrus (BA 9)	R	719	52	18	32	4.64	3.71	0.044
<i>Inferior frontal gyrus (BA 45)</i>	R		56	24	8	4.44	3.60	
<i>Inferior frontal gyrus (BA 9)</i>	R		42	2	32	4.35	3.55	
AD NVH < CN								
Uncus (BA 28)	R	1124	20	-2	-30	6.37	4.55	0.009
<i>Inferior temporal gyrus (BA 20)</i>	R		30	-12	-34	6.01	4.40	
<i>Uncus (BA 36)</i>	R		26	-4	-38	5.87	4.33	
Uncus (BA 28)	L	808	-18	0	-28	5.53	4.18	0.033
<i>Uncus (BA 36)</i>	L		-24	-4	-40	5.31	4.07	
<i>Uncus (BA 20)</i>	L		-30	-14	-36	5.11	3.96	

AD: Alzheimer's disease; BA: Brodmann area; CN: cognitively normal; L: left; R: right; TIV: total intracranial volume; VH: visual hallucinations; TIV: total intracranial volume. ^a cluster-level FWE corrected p value.






Figure 1




Figure 2




Figure 3

A multimodal neuroimaging and neuropsychological study of visual hallucinations in Alzheimer's disease

Stefania **Pezzoli**, PhD ^{(1), (2)}, Riccardo **Manca**, PhD ⁽³⁾,

Annachiara **Cagnin**, MD ^{(4), (5)}, Annalena **Venneri**, PhD ^{(3), (6)}

for the Alzheimer's Disease Neuroimaging Initiative*

(1) *Helen Wills Neuroscience Institute, University of California Berkeley, Berkeley, California, USA*

(2) *Molecular Biophysics and Integrated Bioimaging, Lawrence Berkeley National Laboratory, Berkeley, California, USA*

(3) *Department of Life Sciences, Brunel University London, London, UK*

(4) *Department of Neurosciences, University of Padua, Padua, Italy*

(5) *Padua Neuroscience Center (PNC), University of Padua, Padua, Italy*

(6) *Department of Medicine and Surgery, University of Parma, Parma, Italy*

Supplementary Materials

Supplementary methods

It has been suggested that hallucinations and misidentification delusions may define one subtype of AD with psychosis, as opposed to the persecutory delusion subtype [1]. Delusions were identified with the NPI item for delusions. Misidentifications were assessed by answering yes/no to the following questions: “4. Does {P} believe that unwelcome guests are living in his/her house?”; “5. Does {P} believe that his/her spouse or others are not who they claim to be?”, “Does {P} believe that his/her house is not his/her home?”, “Does {P} believe that television or magazine figures are actually present in the home?”. Paranoid delusions

were identified with the following questions: “1. Does {P} believe that he/she is in danger - that others are planning to hurt him/her?”, “2. Does {P} believe that others are stealing from him/her?”, “3. Does {P} believe that his/her spouse is having an affair?”, “7. Does {P} believe that family members plan to abandon him/her?”. Eleven patients with VH and 5 without VH also had delusions. Four had both misidentifications and paranoid delusions (3 VH and 1 NVH), 2 had only misidentifications (2 VH), 7 had only paranoid delusions (4 VH and 3 NVH). For three of the remaining patients with delusions (2 VH and 1 NVH) to the question “Does {P} believe any other unusual things that I haven't asked about?” had been answered with a ‘yes’.

Differences in regional glucose metabolism were assessed between the whole AD sample and CN participants, and between each AD sub-group and CN. Further analyses were carried out to explore the cingulate island sign (CIS) that refers to the relative preservation of metabolism of the posterior cingulate relative to the precuneus and cuneus detected with FDG-PET imaging in DLB. It has been included as a supportive biomarker of DLB, and it has been shown to differentiate DLB from AD [2–4]. In fact, AD is characterized by more prominent parietotemporal and posterior cingulate hypometabolism [5]. To determine glucose metabolism in the posterior cingulate and to calculate the CIS ratio, ROIs were placed in the posterior cingulate, and in the cuneus plus precuneus. ROIs were created with the WFU PickAtlas toolbox, and the signal was extracted for each participant using the MarsBar toolbox. We calculated the CIS ratio by dividing the mean value in the posterior cingulate ROI by the mean value in the precuneus plus cuneus ROI. SPSS 22 was used to assess between group differences in the CIS ratio and signal in the posterior cingulate using a one-way ANOVA.

Supplementary results

No differences between patients with and without VH were found in the proportion of patients with comorbid delusions ($p=0.13$), and in those with misidentifications ($p=0.59$) and paranoid delusions ($p=1.00$) taken separately.

The whole AD sample was compared with CN matched participants. No differences were detected in age, gender, years of education. AD patients presented poorer performance in all neuropsychological tests, and higher scores on the NPI. Details are reported in Table S1.

When AD with and without VH were compared, no between-group differences were observed in age, gender, years of education, MMSE, NPI scores, and presence of neuropsychiatric symptoms other than VH (Table S2). Although not surviving correction for multiple comparisons ($p < 0.005$), the only neuropsychological test that reached statistical significance was the TMT-A (Table S2).

In the comparison between AD and CN, FDG-PET analysis revealed a pattern of glucose metabolism consistent with the one usually observed in AD. Specifically, regions of hypometabolism were found in temporal and parietal areas, including the left posterior cingulate, consistent with a diagnosis of AD [6]. Details are shown in Table S4 and displayed in Figure S1.

One-way ANOVA analyses reported significant differences between groups in the posterior cingulate ROI, $F(2,30) = 10.31$, $p < 0.001$. Bonferroni *post-hoc* comparisons revealed significant differences between cognitively normal participants and patients with VH ($p < 0.001$) and without VH ($p = 0.036$), but no differences between VH and NVH groups ($p = 0.229$). No significant differences were found between groups in the CIS ratio (one-way ANOVA analysis, $p = 0.084$).

Supplementary tables

Table S1 Demographic, clinical and neuropsychological characteristics for AD patients and cognitively normal controls (PET sub-study).

Characteristic	AD		CN		p value
	n	Mean (SD)	n	Mean (SD)	
<i>Demographics</i>					
Age	22	74.05 (8.01)	22	74.18 (6.88)	0.65 ^a
Gender M:F	22	8:14	22	8:14	-
Years of education	22	16.32 (2.77)	22	16.73 (3.13)	0.16 ^c
<i>Clinical and neuropsychological features</i>					
MMSE	22	22.36 (3.82)	22	29.09 (1.02)	<0.001 ^c
NPI total score	22	21.36 (21.51)	22	0.00 (0.00)	<0.001 ^c
TMT-A (s)	21	74.86 (42.04)	22	33.45 (9.90)	<0.001 ^c
TMT-B (s)	21	229.10 (88.97)	22	82.32 (40.22)	<0.001 ^c
Prose memory:					
Immediate recall	21	4.05 (3.15)	22	15.50 (2.99)	<0.001 ^c
Delayed recall	21	1.67 (2.48)	22	14.23 (3.52)	<0.001 ^c
RAVLT:					
Immediate recall	21	23.76 (7.63)	22	44.77 (7.80)	<0.001 ^c
Delayed recall	21	0.76 (1.92)	22	7.77 (3.44)	<0.001 ^c
Category fluency	21	12.29 (3.58)	22	23.36 (5.28)	<0.001 ^a
Clock drawing	21	3.00 (1.61)	22	4.64 (0.58)	<0.001 ^c
Clock copying	21	4.05 (1.12)	22	4.91 (0.29)	0.001 ^c
Boston naming test	19	23.21 (5.50)	22	28.45 (1.76)	<0.001 ^c

AD: Alzheimer's disease; CN: cognitively normal; F: female; M: male; MMSE: Mini-Mental State Examination; RAVLT: Rey Auditory Verbal Learning Test; SD: standard deviation; TMT: Trail Making Test. ^a Independent-sample t-test; ^b Fisher's Exact Test; ^c Mann-Whitney U test.

Table S2 Differences in demographic, clinical and neuropsychological features between AD VH and NVH (PET sub-study). Mean and SD are reported for each variable unless otherwise specified.

Characteristic	AD VH		AD NVH		p value
	n		n		
<i>Demographics</i>					
Age	11	73.73 (8.99)	11	74.27 (6.88)	0.87 ^a
Gender M:F	11	4:7	11	4:7	1.00 ^b
Years of education	11	16.82 (2.78)	11	15.82 (2.79)	0.40 ^c
<i>Clinical features</i>					
MMSE	11	22.27 (4.86)	11	22.45 (2.66)	0.91 ^a
NPI total score	11	22.91 (18.99)	11	19.82 (24.62)	0.33 ^c
NPI tot - NPI VH	11	19.45 (18.51)	11	19.82 (24.62)	0.75 ^c
Delusions, n (%)	11	6 (54.5%)	11	1 (9.1%)	0.10 ^b
Hallucinations, n (%)	11	11 (100%)	11	0 (0.0%)	<0.001 ^b
Agitation/aggression, n (%)	11	8 (72.7%)	11	5 (45.5%)	0.19 ^b
Depression/dysphoria, n (%)	11	7 (63.6%)	11	5 (45.5%)	0.39 ^b
Anxiety, n (%)	11	7 (63.6%)	11	4 (36.4%)	0.20 ^b
Elation/euphoria, n (%)	11	0 (0.0%)	11	2 (18.2%)	0.14 ^b
Apathy/indifference, n (%)	11	2 (18.2%)	11	8 (72.7%)	0.01 ^b
Disinhibition, n (%)	11	2 (18.2%)	11	4 (36.4%)	0.34 ^b
Irritability/lability, n (%)	11	5 (45.5%)	11	5 (45.5%)	1.00 ^b
Aberrant motor behavior, n (%)	11	2 (18.2%)	11	4 (36.4%)	0.34 ^b
Sleep, n (%)	11	5 (45.5%)	11	5 (45.5%)	1.00 ^b
Appetite and eating disorders, n (%)	11	4 (36.4%)	11	2 (18.2%)	0.34 ^b
<i>Neuropsychological features</i>					
TMT-A (s)	10	95.60 (45.68)	11	56.00 (28.91)	0.05 ^c
TMT-B (s)	10	257.30 (70.92)	11	203.45 (98.92)	0.31 ^c
Prose memory:					
Immediate recall	10	3.80 (3.71)	11	4.27 (2.72)	0.39 ^c
Delayed recall	10	2.00 (3.27)	11	1.36 (1.57)	0.81 ^c
RAVLT:					
Immediate recall	10	24.20 (9.68)	11	23.36 (5.64)	0.81 ^a
Delayed recall	10	1.20 (2.70)	11	0.36 (0.67)	1.00 ^c
Category fluency	10	11.80 (3.19)	11	12.73 (4.00)	0.57 ^a
Clock drawing	10	2.40 (1.65)	11	3.55 (1.44)	0.11 ^c
Clock copying	10	3.80 (1.13)	11	4.27 (1.10)	0.28 ^c
Boston naming test	9	22.63 (6.61)	11	23.64 (4.84)	0.90 ^c

AD: Alzheimer's disease; CN: cognitively normal; F: female; M: male; MMSE: Mini-Mental State Examination; NVH: no visual hallucinations; RAVLT: Rey Auditory Verbal Learning Test; SD: standard deviation; TMT: Trail Making Test; VH: visual hallucinations. ^a Independent-sample t-test; ^b Fisher's Exact Test; ^c Mann-Whitney U test.

Table S3 Differences in pharmacological treatments between patient groups.

Medication type	AD VH	AD NVH	χ^2	p
MRI study	n = 24	n = 24		
NMDA block (Y/N)	10/14	8/16	0.356	0.551
AChE inhibitors (Y/N)	16/8	17/7	0.097	0.755
Antidepressant (Y/N)	9/15	7/17	0.375	0.540
Other behavioral (Y/N)	3/21	1/23	1.091	0.296
PET study	n = 11	n = 11		
NMDA block (Y/N)	7/4	4/7	1.636	0.201
AChE inhibitors (Y/N)	10/1	8/3	1.222	0.269
Antidepressant (Y/N)	6/5	4/7	0.733	0.392
Other behavioral (Y/N)	3/8	0/11	3.474	0.620

AChE: acetylcholinesterase; AD: Alzheimer's disease; NMDA: N-methyl-D-aspartate; NVH: no visual hallucinations; VH: visual hallucinations.

Table S4 Regions of hypometabolism in AD patients compared with CN (FWE-corrected cluster-level threshold of $p < 0.05$ with TIV and age as covariates of no interest).

Structure	Side	Cluster size	MNI coordinates			T score	Z score	p value
Uncus (BA 28)	L	1355	-28	-10	-36	7.59	5.94	<0.001
<i>Fusiform gyrus (BA 37)</i>	L		-28	-34	-16	6.69	5.45	
<i>Parahippocampal gyrus (BA 27)</i>	L		-12	-38	-2	5.93	4.99	
Posterior cingulate (BA 23)	L	1757	0	-50	22	7.70	5.99	<0.001
<i>Cuneus (BA 7)</i>	L		-4	-70	30	6.66	5.43	
<i>Parahippocampal gyrus (BA 27)</i>	R		16	-38	-2	5.48	4.71	
Cerebellum - uvula	R	74	6	-92	-50	7.26	5.77	0.005
Inferior temporal gyrus (BA 20)	R	1096	62	-26	-24	7.04	5.64	<0.001
<i>Middle temporal gyrus (BA 21)</i>	R		64	-40	-10	6.10	5.10	
Inferior temporal gyrus (BA 20)	L	851	-60	-26	-24	7.01	5.63	<0.001
<i>Inferior temporal gyrus (BA 20)</i>	L		-58	-48	-16	6.30	5.22	
<i>Inferior temporal gyrus (BA 20)</i>	L		-52	-12	-36	5.63	4.80	
Uncus	R	730	30	-12	-34	7.61	5.95	<0.001
Precuneus	R	315	44	-64	40	6.24	5.18	<0.001
Inferior parietal lobule (BA 39)	L	453	-46	-66	42	6.20	5.16	<0.001
<i>Superior parietal lobule (BA 7)</i>	L		-32	-78	44	5.79	4.91	
Cerebellum - tonsil	L	29	-50	-60	-42	5.93	4.99	0.014
Cerebellum - tonsil	R	45	56	-60	-40	5.61	4.79	0.009
Parahippocampal gyrus (BA 36)	R	25	30	-32	-22	5.45	4.68	0.016

AD: Alzheimer's disease; BA: Brodmann area; CN: cognitively normal; L: left; R: right; TIV: total intracranial volume.

Table S5 Biomarker profiles for AD patients with and without VH and CN. Mean and SD are reported for each variable unless otherwise specified.

Biomarker	AD VH		AD NVH		CN		p value
	n		n		n		
<i>MRI sub-study</i>							
CSF A β ₁₋₄₂ (pg/mL)	19	589.97 (139.46)	20	769.91 (504.73)	18	1167.82 (655.49)	0.002 ^a
CSF P-tau (pg/mL)	19	38.56 (20.28)	20	32.13 (8.44)	18	21.23 (7.69)	0.001 ^a
CSF P-tau/A β ₁₋₄₂	19	0.070 (0.040)	20	0.051 (0.019)	18	0.026 (0.020)	< 0.001 ^a
A β positivity (A β + / A β -)	19	19/0 ^b	20	17/3 ^b	18	10/8 ^b	0.016 ^c
P-tau positivity (P-tau+ / P-tau-)	19	17/2 ^b	20	18/2 ^b	18	6/12 ^b	0.001 ^c
¹⁸ F-AV45 PET SUVR	21	1.38 (0.17)	22	1.36 (0.21)	22	1.14 (0.18)	< 0.001 ^a
¹⁸ F-AV45 PET positivity (AV45+ / AV45-)	21	20/1 ^b	22	19/3 ^b	22	10/12 ^b	0.002 ^c
A+T+ (y/n)	19	17/2 ^b	20	18/2 ^b	18	6/12 ^b	0.001 ^c
<i>FDG-PET sub-study</i>							
CSF A β ₁₋₄₂ (pg/mL)	11	597.51 (124.05)	9	888.83 (717.37)	9	1376.18 (683.26)	0.016 ^a
CSF P-tau (pg/mL)	11	42.73 (22.17)	9	28.78 (7.73)	9	23.15 (8.99)	0.022 ^a
CSF P-tau/A β ₁₋₄₂	11	0.074 (0.037)	9	0.044 (0.18)	9	0.023 (0.020)	0.001 ^a
A β positivity (A β + / A β -)	11	11/0 ^b	9	8/1 ^b	9	3/6 ^b	0.001 ^c
P-tau positivity (P-tau+ / P-tau-)	11	11/0 ^b	9	8/1 ^b	9	3/6 ^b	0.001 ^c
¹⁸ F-AV45 PET SUVR	10	1.44 (0.17)	11	1.35 (0.23)	11	1.13 (0.19)	0.004 ^a
¹⁸ F-AV45 PET positivity (AV45+ / AV45-)	10	10/0 ^b	11	9/2 ^b	11	4/7 ^b	0.004 ^c
A+T+ (y/n)	11	11/0 ^b	9	8/1 ^b	9	3/6 ^b	0.001 ^c

A β : amyloid beta; CSF: cerebrospinal fluid; NVH: no visual hallucinations; PET: positron emission tomography; P-tau: phosphorylated tau; SUVR: standardized uptake value ratio; VH: visual hallucinations; WM: white matter. ^a One-way ANOVA; ^b frequency; ^c χ^2 .

Table S6 Regions of lower gray matter volume in patients with AD with VH only and matched NVH compared with CN (FWE-corrected cluster-level threshold of $p < 0.05$ with TIV and age as covariates of no interest, $k > 130$).

Structure	Side	Cluster size	MNI coordinates			T score	Z score	p value ^a
AD VH < CN								
Superior temporal gyrus (BA 38)	L	2694	-33	6	-18	7.07	4.95	<0.001
<i>Parahippocampal gyrus (BA 34)</i>	L		-30	2	-24	6.71	4.80	
<i>Amygdala</i>	L		-24	-6	-15	6.42	4.68	
Superior temporal gyrus (BA 22)	L	926	-52	-16	-8	6.77	4.83	0.002
<i>Middle temporal gyrus (BA 21)</i>	L		-54	-28	-3	5.13	4.05	
<i>Middle temporal gyrus (BA 21)</i>	L		-64	-40	-8	5.07	4.02	
Middle occipital gyrus (BA 19)	L	2217	-51	-80	2	6.44	4.69	<0.001
<i>Middle temporal gyrus (BA 19)</i>	L		-42	-81	21	5.27	4.12	
<i>Middle temporal gyrus (BA 37)</i>	L		-50	-48	-6	5.24	4.11	
Superior temporal gyrus (BA 38)	R	1645	36	8	-21	5.96	4.47	<0.001
<i>Amygdala</i>	R		27	-6	-18	5.72	4.35	
<i>Medial globus pallidus</i>	R		16	-4	-9	4.55	3.73	
Middle occipital gyrus (BA 19)	R	777	46	-80	4	5.51	4.25	0.005
<i>Middle occipital gyrus (BA 18)</i>	R		42	-86	-4	5.09	4.03	
<i>Inferior occipital gyrus (BA 18)</i>	R		33	-80	-6	4.45	3.67	
Middle occipital gyrus (BA 18)	R	598	24	-90	14	5.17	4.07	0.018
<i>Middle occipital gyrus (BA 18)</i>	R		12	-96	12	4.70	3.81	
<i>Cuneus (BA 18)</i>	L		-2	-86	18	4.41	3.64	
Supramarginal gyrus (BA 40)	L	633	-54	-51	36	4.71	3.82	0.014
<i>Superior temporal gyrus (BA 22)</i>	L		-52	-46	12	4.71	3.82	
<i>Supramarginal gyrus (BA 40)</i>	L		-56	-51	21	4.69	3.81	
AD NVH < CN								
Posterior cingulate gyrus (BA 31)	L	63833	-8	-45	32	8.56	5.49	<0.001
<i>Supramarginal gyrus (BA 40)</i>	L		-50	-54	26	8.34	5.42	
<i>Fusiform gyrus (BA 37)</i>	L		-52	-48	-6	7.85	5.25	
<i>Amygdala</i>	L		-22	-9	-18	7.50	5.12	
<i>Uncus – amygdala</i>	R		27	-3	-24	7.45	5.10	
<i>Middle temporal gyrus (BA 39)</i>	L		-48	-74	10	7.33	5.05	
<i>Posterior cingulate gyrus (BA 31)</i>	L		-6	-58	21	7.30	5.04	
<i>Precuneus (BA 19)</i>	L		-33	-74	39	7.08	4.95	
<i>Amygdala</i>	L		-27	-4	-22	7.04	4.94	

<i>Precuneus (BA 7)</i>	L		-4	-69	39	7.01	4.92	
<i>Precuneus (BA 7)</i>	L		-15	-72	45	6.97	4.91	
<i>Middle temporal gyrus (BA 37)</i>	L		-56	-62	-3	6.96	4.90	
<i>Precentral gyrus (BA 6)</i>	L		-44	-9	36	6.92	4.89	
<i>Parahippocampal gyrus (BA 36)</i>	L		-28	-38	-9	6.85	4.96	
<i>Inferior temporal gyrus (BA 20)</i>	R		57	-21	-24	6.74	4.81	
<i>Middle temporal gyrus (BA 22)</i>	L		-58	-38	3	6.71	4.80	
<i>Paracentral lobule (BA 5)</i>	L	758	-6	-33	51	5.67	4.33	0.004
<i>Precuneus (BA 7)</i>	L		-10	-46	52	4.58	3.74	
<i>Paracentral lobule (BA 6)</i>	R		10	-36	56	4.38	3.63	
<i>Paracentral lobule (BA 5)</i>	R		8	-34	51	4.35	3.61	
<i>Precuneus (BA 7)</i>	R		10	-45	51	4.26	3.55	
<i>Paracentral lobule (BA 31)</i>	L		-6	-21	50	4.24	3.54	

AD: Alzheimer's disease; BA: Brodmann area; CN: cognitively normal; L: left; NVH: no visual hallucinations; R: right; TIV: total intracranial volume; k: cluster-extent based threshold; VH: visual hallucinations.

Table S7 Regions of hypometabolism in patients with AD with VH only compared with CN (FWE-corrected cluster-level threshold of $p < 0.05$ with TIV and age as covariates of no interest, $k > 1500$).

Structure	Side	Cluster size	MNI coordinates			T score	Z score	p value ^a
AD VH < CN								
<i>Middle temporal gyrus (BA 37)</i>	L	410	-50	-66	-2	11.55	4.21	0.020
<i>Middle temporal gyrus (BA 37)</i>	L		-54	-54	-14	6.49	3.42	
<i>Middle temporal gyrus (BA 37)</i>	L		-58	-56	-4	5.74	3.23	

AD: Alzheimer's disease; BA: Brodmann area; CN: cognitively normal; L: left; R: right; TIV: total intracranial volume; k: cluster-extent based threshold; VH: visual hallucinations.

Table S8 Differences in ROI volumes and metabolism between AD VH, AD NVH and CN (ANOVA). Bonferroni adjusted p-values from pairwise tests (*post hoc* comparisons) are reported.

ROI	AD VH	AD NVH	CN	<i>F</i> (p)	<i>Post hoc</i> comparisons (p)		
	Mean (SD)	Mean (SD)	Mean (SD)		VH-NVH	VH-CN	NVH-CN
<i>MRI</i>	<i>n</i> = 24	<i>n</i> = 24	<i>n</i> = 24				
L Calcarine	6.30 (1.09)	6.51 (1.28)	7.14 (1.11)	3.35 (0.041)	1.000	0.046	0.204
R Calcarine	5.32 (0.90)	5.54 (1.07)	6.11 (0.99)	4.08 (0.021)	1.000	0.021	0.152
L Cuneus	3.53 (0.58)	3.68 (0.63)	3.95 (0.58)	3.03 (0.055)	1.000	0.053	0.370
R Cuneus	3.26 (0.58)	3.53 (0.57)	3.79 (0.61)	4.92 (0.010)	0.357	0.008	0.372
L IOG	2.46 (0.38)	2.50 (0.44)	2.80 (0.38)	5.19 (0.008)	1.000	0.013	0.035
R IOG	2.67 (0.45)	2.80 (0.42)	3.01 (0.45)	3.60 (0.033)	0.947	0.029	0.313
L MOG	7.72 (1.18)	7.91 (1.39)	8.79 (1.12)	5.10 (0.009)	1.000	0.012	0.049
R MOG	5.47 (0.93)	5.70 (0.96)	6.14 (0.80)	3.49 (0.036)	1.000	0.034	0.273
L SOG	2.58 (0.48)	2.71 (0.53)	2.92 (0.42)	3.16 (0.007)	1.000	0.046	0.381
R SOG	3.07 (0.57)	3.29 (0.52)	3.54 (0.56)	4.33 (0.017)	0.502	0.013	0.381
L FG	8.34 (1.11)	8.40 (1.35)	9.31 (1.01)	5.24 (0.008)	1.000	0.015	0.026
R FG	10.46 (1.24)	10.67 (1.41)	11.16 (1.22)	1.83 (0.168)	1.000	0.198	0.595
L LG	6.13 (0.94)	6.29 (1.05)	6.91 (1.05)	3.86 (0.026)	1.000	0.032	0.120
R LG	6.15 (0.95)	6.38 (1.05)	6.97 (1.00)	4.23 (0.018)	1.000	0.018	0.135
L Hippocampus	2.50 (0.51)	2.48 (0.49)	3.14 (0.45)	14.54 (< 0.001)	1.000	<0.001	<0.001
R Hippocampus	3.15 (0.55)	3.21 (0.54)	3.65 (0.45)	6.78 (0.002)	1.000	0.004	0.012
L PCC	1.36 (0.20)	1.31 (0.27)	1.52 (0.23)	5.31 (0.007)	1.000	0.062	0.008
R PCC	0.65 (0.10)	0.62 (0.14)	0.72 (0.11)	4.95 (0.010)	1.000	0.106	0.009
<i>PET</i>	<i>n</i> = 11	<i>n</i> = 11	<i>n</i> = 11				
L Calcarine	20.81 (1.18)	23.41 (2.12)	24.50 (2.34)	10.46 (< 0.001)	0.011	<0.001	0.601
R Calcarine	17.65 (0.97)	20.02 (1.91)	20.83 (2.22)	9.47 (< 0.001)	0.012	<0.001	0.891
L Cuneus	14.29 (1.03)	16.08 (1.89)	17.32 (1.86)	9.46 (< 0.001)	0.048	<0.001	0.262
R Cuneus	13.76 (0.96)	15.61 (1.83)	16.74 (1.78)	10.00 (< 0.001)	0.030	<0.001	0.309
L IOG	7.48 (0.54)	8.38 (1.23)	8.69 (0.62)	5.98 (0.007)	0.059	0.007	1.000
R IOG	7.78 (0.90)	8.79 (1.25)	9.01 (0.60)	5.22 (0.011)	0.056	0.015	1.000
L MOG	24.46 (1.88)	27.62 (4.52)	29.07 (2.39)	6.18 (0.006)	0.076	0.005	0.865
R MOG	16.09 (1.67)	18.05 (3.09)	19.07 (1.36)	5.30 (0.011)	0.130	0.010	0.847
L SOG	12.64 (1.25)	14.16 (2.15)	15.61 (1.56)	8.48 (0.001)	0.130	<0.001	0.161
R SOG	13.24 (1.42)	14.97 (2.21)	16.53 (1.69)	9.15 (< 0.001)	0.095	<0.001	0.157
L FG	15.81 (1.37)	16.68 (1.82)	17.94 (0.82)	6.46 (0.005)	0.466	0.004	0.128
R FG	17.45 (1.59)	18.40 (2.42)	19.91 (0.93)	5.44 (0.010)	0.647	0.008	0.161
L LG	17.72 (1.00)	19.30 (1.37)	19.74 (1.22)	8.56 (0.001)	0.014	0.001	1.000
R LG	19.14 (1.26)	20.62 (1.56)	21.41 (1.36)	7.49 (0.002)	0.057	0.002	0.574
L Hippocampus	5.51 (0.58)	5.38 (0.46)	6.01 (0.40)	5.35 (0.010)	1.000	0.066	0.012

R Hippocampus	5.56 (0.49)	5.44 (0.42)	6.03 (0.33)	6.20 (0.006)	1.000	0.037	0.007
L PCC	4.09 (0.53)	4.63 (0.78)	5.31 (0.53)	10.47 (< 0.001)	0.160	<0.001	0.048
R PCC	2.42 (0.26)	2.43 (0.39)	2.92 (0.22)	10.00 (< 0.001)	1.000	0.001	0.002

AD: Alzheimer's disease; CN: cognitively normal; FG: Fusiform gyrus; IOG: Inferior occipital gyrus; L: left; LG: Lingual gyrus, MOG: Middle occipital gyrus; NVH: no VH; PCC: Posterior cingulate cortex; R: Right; ROI: Region of interest; SD: standard deviation; SOG: Superior occipital gyrus; VH: visual hallucinations.

Table S9 Correlations between volume and metabolism in each GM ROI (Bonferroni-adjusted $p = 0.05/18 = 0.003$).

ROI	Whole sample ($n = 33$)	AD VH ($n = 11$)	AD NVH ($n = 11$)	CN ($n = 11$)
L Calcarine	$\rho = 0.43, p = 0.012$	$\rho = 0.32, p = 0.340$	$\rho = 0.24, p = 0.484$	$\rho = 0.32, p = 0.340$
R Calcarine	$\rho = 0.45, p = 0.009$	$\rho = 0.54, p = 0.089$	$\rho = 0.25, p = 0.467$	$\rho = 0.32, p = 0.340$
L Cuneus	$\rho = 0.40, p = 0.020$	$\rho = 0.36, p = 0.272$	$\rho = 0.14, p = 0.689$	$\rho = 0.27, p = 0.417$
R Cuneus	$\rho = 0.39, p = 0.024$	$\rho = 0.41, p = 0.212$	$\rho = 0.13, p = 0.709$	$\rho = 0.22, p = 0.519$
L IOG	$\rho = 0.22, p = 0.208$	$\rho = 0.39, p = 0.235$	$\rho = -0.30, p = 0.370$	$\rho = 0.23, p = 0.502$
R IOG	$\rho = 0.34, p = 0.054$	$\rho = 0.19, p = 0.574$	$\rho = 0.17, p = 0.612$	$\rho = 0.35, p = 0.285$
L MOG	$\rho = 0.10, p = 0.567$	$\rho = 0.19, p = 0.574$	$\rho = -0.20, p = 0.555$	$\rho = -0.14, p = 0.689$
R MOG	$\rho = 0.27, p = 0.123$	$\rho = 0.38, p = 0.247$	$\rho = 0.00, p = 1.000$	$\rho = 0.22, p = 0.519$
L SOG	$\rho = 0.21, p = 0.243$	$\rho = 0.01, p = 0.979$	$\rho = -0.25, p = 0.450$	$\rho = 0.39, p = 0.235$
R SOG	$\rho = 0.37, p = 0.034$	$\rho = 0.28, p = 0.401$	$\rho = 0.10, p = 0.770$	$\rho = 0.42, p = 0.201$
L FG	$\rho = 0.35, p = 0.045$	$\rho = 0.63, p = 0.039$	$\rho = -0.13, p = 0.709$	$\rho = 0.39, p = 0.235$
R FG	$\rho = 0.19, p = 0.287$	$\rho = -0.05, p = 0.873$	$\rho = -0.01, p = 0.979$	$\rho = 0.42, p = 0.201$
L LG	$\rho = 0.29, p = 0.101$	$\rho = 0.25, p = 0.467$	$\rho = -0.21, p = 0.537$	$\rho = 0.08, p = 0.811$
R LG	$\rho = 0.37, p = 0.034$	$\rho = 0.44, p = 0.180$	$\rho = 0.05, p = 0.873$	$\rho = 0.14, p = 0.689$
L Hippocampus	$\rho = 0.58, p < 0.001$	$\rho = 0.53, p = 0.096$	$\rho = 0.33, p = 0.312$	$\rho = 0.50, p = 0.117$
R Hippocampus	$\rho = 0.52, p = 0.002$	$\rho = 0.45, p = 0.160$	$\rho = 0.21, p = 0.537$	$\rho = 0.48, p = 0.133$
L PCC	$\rho = 0.43, p = 0.012$	$\rho = 0.35, p = 0.285$	$\rho = 0.48, p = 0.133$	$\rho = 0.34, p = 0.312$
R PCC	$\rho = 0.37, p = 0.032$	$\rho = 0.19, p = 0.574$	$\rho = 0.14, p = 0.689$	$\rho = 0.44, p = 0.180$

AD: Alzheimer's disease; CN: cognitively normal; FG: Fusiform gyrus; IOG: Inferior occipital gyrus; L: left; LG: Lingual gyrus, MOG: Middle occipital gyrus; NVH: no VH; PCC: Posterior cingulate cortex; R: Right; ROI: Region of interest; SD: standard deviation; SOG: Superior occipital gyrus; VH: visual hallucinations.

Table S10 Regions of lower gray matter volume in AD patients with dementia with ($n = 18$) and without VH ($n = 18$) independently compared with CN ($n = 18$) (FWE-corrected cluster-level threshold of $p < 0.05$ with TIV and age as covariates of no interest).

Structure		Cluster size	MNI coordinates			T score	Z score	p value
AD VH < CN								
Inferior frontal gyrus (BA 47)	R	11848	34	9	-21	8.88	6.26	<0.001
<i>Parahippocampal gyrus (amygdala)</i>	R		26	-9	-15	6.85	5.33	
<i>Parahippocampal gyrus (BA 34)</i>	R		15	2	-15	5.67	4.68	
Parahippocampal gyrus (amygdala)	L	15723	-26	-9	-15	7.79	5.79	<0.001
<i>Superior temporal gyrus (BA 38)</i>	L		-34	6	-16	7.44	5.36	
<i>Parahippocampal gyrus (BA 36)</i>	L		-27	-39	-8	6.91	5.37	
Middle occipital gyrus (BA 19)	L	4271	-34	-90	10	6.34	5.06	<0.001
<i>Middle occipital gyrus (BA 19)</i>	L		-52	-75	4	6.30	5.04	
<i>Middle occipital gyrus (BA 18)</i>	L		-32	-96	-6	5.71	4.70	
Middle occipital gyrus (BA 18)	R	8498	24	-90	12	6.21	5.00	<0.001
<i>Superior occipital gyrus (BA 19)</i>	R		39	-81	26	5.74	4.73	
<i>Superior temporal gyrus (BA 39)</i>	R		60	-64	15	5.25	4.43	
Thalamus	L	1510	-2	-2	3	5.99	4.87	<0.001
<i>Thalamus</i>	L		-14	-10	16	5.46	4.55	
<i>Caudate nucleus (head)</i>	R		8	8	3	5.06	4.31	
Inferior parietal Lobule (BA 40)	R	683	58	-50	38	5.09	4.33	0.011
<i>Inferior parietal Lobule (BA 40)</i>	R		63	-36	39	4.84	4.16	
Inferior temporal gyrus (BA 20)	R	2771	60	-18	-22	4.97	4.24	<0.001
<i>Superior temporal gyrus (BA 22)</i>	R		51	-22	-2	4.96	4.24	
<i>Middle temporal gyrus (BA 21)</i>	R		66	-27	-3	4.92	4.21	
AD NVH < CN								
Uncus (BA 34)	L	15875	-14	-4	-24	8.91	6.27	<0.001
<i>Hippocampus</i>	L		-26	-12	-16	6.77	5.29	
<i>Hippocampus</i>	L		-32	-36	-8	6.58	5.19	
Precuneus (BA 7)	L	5448	-18	-68	33	6.65	5.23	<0.001
<i>Superior temporal gyrus (BA 13)</i>	L		-46	-52	26	5.39	4.51	
<i>Posterior cingulate gyrus (BA 38)</i>	L		-8	-58	8	4.76	4.11	
Parahippocampal gyrus (amygdala)	R	16344	20	-9	-12	6.39	5.09	<0.001
<i>Hippocampus</i>	R		30	-8	-22	5.87	4.80	
<i>Superior temporal gyrus (BA 38)</i>	R		24	18	-38	5.65	4.67	
Posterior cingulate (BA 31)	L	876	-6	-56	26	6.18	5.22	0.013
<i>Precuneus (BA 31)</i>	L		-9	-46	32	5.99	5.10	
<i>Superior temporal gyrus (BA 38)</i>	R		24	18	-36	5.79	5.01	
Superior frontal gyrus (BA 10)	L	677	-20	50	30	5.00	4.27	0.036
<i>Middle frontal gyrus (BA 8)</i>	L		-21	33	45	4.65	4.04	
<i>Middle frontal gyrus (BA 9)</i>	L		-30	39	28	4.55	3.97	
Medial frontal gyrus (BA 10)	R	2176	3	60	6	4.92	4.22	<0.001
<i>Medial frontal gyrus (BA 10)</i>	R		3	64	16	4.51	3.94	
<i>Superior frontal gyrus (BA 10)</i>	L		-4	64	2	4.43	3.88	
Precentral gyrus (BA 4)	L	1526	-38	-18	42	4.67	4.05	0.001

<i>Postcentral gyrus (BA 1)</i>	L	-48	-26	57	4.63	4.02
<i>Precentral gyrus (BA 4)</i>	L	-34	-22	64	4.62	4.01

AD: Alzheimer's disease; CN: cognitively normal; BA: Brodmann area; L: left; R: right; VH: visual hallucinations.

Table S11 Regions of hypometabolism in AD patients with dementia with ($n = 9$) and without VH ($n = 9$) independently compared with CN ($n = 9$) (FWE-corrected cluster-level threshold of $p < 0.05$ with TIV and age as covariates of no interest).

Structure	Side	Cluster size	MNI coordinates			T score	Z score	p value ^a
AD VH < CN								
Middle temporal gyrus (BA 39)	R	32231	56	-70	18	10.66	5.48	<0.001
<i>Middle temporal gyrus (BA 39)</i>	R		42	-78	24	9.13	5.13	
<i>Inferior temporal gyrus (BA 20)</i>	R		66	-24	-22	8.64	5.01	
<i>Superior parietal lobule (BA 7)</i>	L		-30	-78	46	8.60	5.00	
<i>Cerebellum (tuber)</i>	R		24	-88	-38	8.25	4.90	
<i>Middle occipital gyrus (BA 18)</i>	L		-36	-96	2	8.18	4.88	
<i>Cerebellum (uvula)</i>	L		-14	-88	-32	7.59	4.71	
<i>Precuneus (BA 19)</i>	R		40	-76	42	7.18	4.58	
<i>Middle occipital gyrus (BA 37)</i>	R		56	-64	-12	7.00	4.52	
<i>Posterior cingulate gyrus (BA 29)</i>	L		-4	-50	12	6.88	4.48	
<i>Posterior cingulate gyrus (BA 30)</i>	L		0	-68	6	6.87	4.48	
<i>Superior occipital gyrus (BA 19)</i>	L		-32	-90	22	6.86	4.47	
<i>Inferior temporal gyrus (BA 20)</i>	L		-58	-22	-26	6.83	4.46	
<i>Inferior parietal lobule (BA 39)</i>	R		50	-66	40	6.80	4.45	
<i>Inferior temporal gyrus (BA 20)</i>	L		-60	-26	-24	6.79	4.45	
<i>Cerebellum (tonsil)</i>	R		52	-52	-44	6.77	4.44	
AD NVH < CN								
Uncus (BA 28)	L	2450	-18	0	-28	7.63	4.72	<0.001
<i>Superior temporal gyrus (BA 38)</i>	L		-20	16	-50	7.27	4.61	
<i>Uncus (BA 36)</i>	L		-24	-4	-40	6.83	4.46	
Uncus (BA 28)	R	1056	22	-2	-30	6.46	4.33	0.008
<i>Uncus (BA 20)</i>	R		30	-12	-34	6.00	4.15	
<i>Superior temporal gyrus (BA 38)</i>	R		38	10	-22	4.26	3.36	

AD: Alzheimer's disease; BA: Brodmann area; CN: cognitively normal; L: left; R: right; TIV: total intracranial volume; VH: visual hallucinations. ^a cluster-level FWE corrected p value.

Table S12 Regions of lower gray matter volume in AD patients with dementia with VH only ($n = 10$) and matched NVH ($n = 10$) compared with CN ($n = 10$) (FWE-corrected cluster-level threshold of $p < 0.05$ with TIV and age as covariates of no interest).

Structure		Cluster size	MNI coordinates			T score	Z score	p value
AD VH < CN								
Superior temporal gyrus (BA 38)	L	1196	-33	4	-16	8.26	5.09	<0.001
<i>Parahippocampal gyrus (amygdala)</i>	L		-26	-4	-16	6.70	4.56	
Superior temporal gyrus (BA 38)	R	687	38	9	-21	6.92	4.64	0.006
<i>Parahippocampal gyrus (amygdala)</i>	R		22	-8	-14	5.05	3.85	
<i>Parahippocampal gyrus (amygdala)</i>	R		28	-4	-20	4.73	3.69	
Middle occipital gyrus (BA 19)	L	1770	-51	-80	2	5.54	4.08	<0.001
<i>Supramarginal gyrus (BA 40)</i>	L		-50	-54	28	5.42	4.03	
<i>Middle temporal gyrus (BA 19)</i>	L		-42	-82	22	5.32	3.98	
Middle occipital gyrus (BA 18)	R	420	12	-98	10	5.20	3.92	0.050
<i>Middle occipital gyrus (BA 18)</i>	R		24	-90	14	5.13	3.89	
AD NVH < CN								
Supramarginal gyrus (BA 40)	L	3868	-48	-52	27	8.46	5.15	<0.001
<i>Middle temporal gyrus (BA 37)</i>	L		-52	-48	-6	7.32	4.78	
<i>Middle temporal gyrus (BA 39)</i>	L		-48	-74	10	6.69	4.56	
Parahippocampal gyrus (amygdala)	L	5607	-22	-9	-18	7.60	4.88	<0.001
<i>Uncus (amygdala)</i>	L		-26	-2	-30	5.83	4.21	
<i>Superior temporal gyrus (BA 38)</i>	L		-38	9	-21	5.82	4.21	
Postcentral gyrus (BA 3)	L	3356	-39	-30	63	7.56	4.87	<0.001
<i>Precentral gyrus (BA 6)</i>	L		-44	-8	56	7.13	4.72	
<i>Middle frontal gyrus (BA 6)</i>	L		-33	4	54	6.90	4.63	
Middle temporal gyrus (BA 21)	R	4879	56	-20	-24	7.45	4.83	<0.001
<i>Medial globus pallidus</i>	R		20	-12	-10	6.47	4.47	
<i>Uncus (amygdala)</i>	R		27	-3	-24	6.24	4.38	
Posterior cingulate gyrus (BA 31)	L	3838	-8	-45	32	7.30	4.78	<0.001
<i>Precuneus (BA 7)</i>	L		-6	-68	40	6.14	4.34	
<i>Posterior cingulate gyrus (BA 31)</i>	L		-6	-58	21	5.89	4.24	
Precuneus (BA 19)	L	1158	-33	-74	39	6.39	4.44	<0.001
<i>Precuneus (BA 7)</i>	L		-24	-63	52	5.91	4.25	
<i>Inferior parietal lobule (BA 39)</i>	L		-40	-66	39	5.69	4.15	
Medial frontal gyrus (BA 8)	R	920	14	33	50	6.29	4.40	0.001
<i>Superior frontal gyrus (BA 8)</i>	L		0	36	51	5.47	4.05	
<i>Superior frontal gyrus (BA 9)</i>	L		-16	40	39	5.42	4.03	
Precentral gyrus (BA 6)	R	1303	40	-9	38	6.23	4.38	<0.001
<i>Postcentral gyrus (BA 3)</i>	R		54	-18	38	6.16	4.35	
<i>Precentral gyrus (BA 4)</i>	R		34	-18	46	5.31	3.98	
Inferior parietal lobule (BA 40)	R	645	56	-48	42	6.02	4.29	0.008
<i>Inferior parietal lobule (BA 40)</i>	R		45	-52	39	5.44	4.04	
<i>Inferior parietal lobule (BA 7)</i>	R		36	-63	44	4.24	3.42	
Rectus gyrus (BA 11)	L	435	-8	15	-21	5.51	4.07	0.046
<i>Inferior frontal gyrus (BA 47)</i>	L		-18	15	-18	4.34	3.48	

AD: Alzheimer's disease; CN: cognitively normal; BA: Brodmann area; L: left; R: right; VH: visual hallucinations.

Table S13 Regions of hypometabolism in AD patients with dementia with VH only ($n = 4$) and matched NVH ($n = 4$) compared with CN ($n = 4$) and between patient groups (FWE-corrected cluster-level threshold of $p < 0.05$ with TIV and age as covariates of no interest).

Structure		Cluster size	MNI coordinates			T score	Z score	p value
AD VH < AD NVH								
Precuneus (BA 7)	R	362	16	-68	28	20.79	4.16	<0.001
<i>Precuneus (BA 31)</i>	R		12	-62	18	17.71	4.01	
<i>Posterior cingulate gyrus (BA 23)</i>	L		-2	-60	18	12.71	3.69	
Inferior temporal gyrus (BA 20)	R	320	64	-26	-26	19.95	4.12	<0.001
<i>Middle temporal gyrus (BA 21)</i>	R		68	-42	-20	15.46	3.89	
<i>Fusiform gyrus (BA 20)</i>	R		46	-28	-28	14.40	3.82	
Inferior parietal lobule (BA 40)	R	188	52	-54	38	17.91	4.02	0.015
<i>Superior temporal gyrus (BA 39)</i>	R		58	-62	24	9.91	3.44	
<i>Supramarginal gyrus (BA 40)</i>	R		62	-46	32	7.65	3.16	
Inferior frontal gyrus (BA 46)	R	184	44	42	8	15.51	3.89	0.017
<i>Middle frontal gyrus (BA 47)</i>	R		46	40	-2	13.40	3.75	
<i>Middle frontal gyrus (BA 47)</i>	R		40	54	8	12.76	3.70	
AD VH < CN								
Parahippocampal gyrus (BA 36)	L	1993	-28	-14	-32	31.77	4.53	<0.001
<i>Middle temporal gyrus (BA 37)</i>	L		-48	-64	-4	28.75	4.45	
<i>Fusiform gyrus (BA 21)</i>	L		-52	-40	-30	25.26	4.33	
Middle frontal gyrus (BA 25)	L	178	-8	10	-22	25.62	4.35	0.037
<i>Parahippocampal gyrus (BA 34)</i>	L		-20	4	-18	8.84	3.32	
Uncus (BA 20)	R	1096	34	-14	-34	23.35	4.27	<0.001
<i>Cerebellum (culmen)</i>	R		30	-34	-26	22.48	4.23	
<i>Inferior temporal gyrus (BA 20)</i>	R		48	-4	-44	18.29	4.04	
AD NVH < CN								
Inferior temporal gyrus (BA 20)	L	233	-42	-4	-44	20.75	4.16	0.008
<i>Inferior temporal gyrus (BA 20)</i>	L		-48	-16	-38	13.08	3.72	
<i>Uncus (BA 20)</i>	L		-32	-10	-42	12.63	3.69	

AD: Alzheimer's disease; CN: cognitively normal; BA: Brodmann area; L: left; R: right; VH: visual hallucinations.

Supplementary figures




Figure S1 Regions of hypometabolism in AD patients compared with CN. The color bar indicates the z scores at a FWE-corrected cluster-level threshold of $p < 0.05$, with TIV and age as covariates of no interest. TIV: total intracranial volume.




Figure S2 Regions of lower gray matter volume in a) AD patients with dementia compared with CN and in b) AD patients with dementia with VH only and matched NVH compared with CN. The color bar indicates the z scores at a FWE-corrected cluster-level threshold of $p < 0.05$, with TIV and age as covariates of no interest. TIV: total intracranial volume.




Figure S3 Regions of hypometabolism in a) AD patients with dementia compared with CN and in b) AD patients with dementia with VH only and matched NVH compared with CN and between patient groups. The color bar indicates the z scores at a FWE-corrected cluster-level threshold of $p < 0.05$, with TIV and age as covariates of no interest. TIV: total intracranial volume.

References

- [1] Cook SE, Miyahara S, Bacanu SA, Perez-Madriñan G, Lopez OL, Kaufer DI, Nimgaonkar VL, Wisniewski SR, DeKosky ST, Sweet RA (2003) Psychotic Symptoms in Alzheimer Disease: Evidence for Subtypes. *Am J Geriatr Psychiatry* **11**, 406–413.
- [2] Graff-Radford J, Murray ME, Lowe VJ, Boeve BF, Ferman TJ, Przybelski SA, Lesnick TG, Senjem ML, Gunter JL, Smith GE, Knopman DS, Jack C. R. J, Dickson DW, Petersen RC, Kantarci K (2014) Dementia with Lewy bodies: basis of cingulate island sign. *Neurology* **83**, 801–809.
- [3] Iizuka T, Kameyama M (2016) Cingulate island sign on FDG-PET is associated with medial temporal lobe atrophy in dementia with Lewy bodies. *Ann Nucl Med* **30**, 421–429.
- [4] McKeith IG, Boeve BF, Dickson DW, Halliday G, Taylor JP, Weintraub D, Aarsland D, Galvin J, Attems J, Ballard CG, Bayston A, Beach TG, Blanc F, Bohnen N, Bonanni L, Bras J, Brundin P, Burn D, Chen-Plotkin A, Duda JE, El-Agnaf O, Feldman H, Ferman TJ, Ffytche D, Fujishiro H, Galasko D, Goldman JG, Gomperts SN, Graff-Radford NR, Honig LS, Iranzo A, Kantarci K, Kaufer D, Kukull W, Lee VMY, Leverenz JB, Lewis S, Lippa C, Lunde A, Masellis M, Masliah E, McLean P, Mollenhauer B, Montine TJ, Moreno E, Mori E, Murray M, O'Brien JT, Orimo S, Postuma RB, Ramaswamy S, Ross OA, Salmon DP, Singleton A, Taylor A, Thomas A, Tiraboschi P, Toledo JB, Trojanowski JQ, Tsuang D, Walker Z, Yamada M, Kosaka K (2017) Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium. *Neurology* **89**, 88–100.
- [5] Sinha N, Firbank M, O'Brien JT (2012) Biomarkers in dementia with Lewy bodies: a review. *Int J Geriatr Psychiatry* **27**, 443–453.
- [6] Dubois B (2018) The Emergence of a New Conceptual Framework for Alzheimer's Disease. *J Alzheimers Dis* **62**, 1059–1066.